BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 649] [Article Influence: 118.7] [Reference Citation Analysis]
Number Citing Articles
1 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
2 Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Eur J Hosp Pharm 2020;27:e41-7. [PMID: 32296504 DOI: 10.1136/ejhpharm-2019-002060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Guardigni V, Badia L, Conti M, Rinaldi M, Mancini R, Viale P, Verucchi G. Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. World J Hepatol 2017; 9(34): 1270-1277 [PMID: 29290908 DOI: 10.4254/wjh.v9.i34.1270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017;9:17-25. [PMID: 28553150 DOI: 10.2147/HMER.S113681] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 13.2] [Reference Citation Analysis]
5 El-sayed MH, Indolfi G. Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination. Semin Liver Dis 2020;40:213-24. [DOI: 10.1055/s-0040-1708812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20:22146. [PMID: 28782335 DOI: 10.7448/ias.20.1.22146] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
7 Elzorkany K, Kora MA, Wahed ASA, Zaghla HE, Zahran AM, Yassein YS, El Naggar AZ, Essa A, Gadallah AA. Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals. Int J Nephrol Renovasc Dis 2020;13:351-8. [PMID: 33273842 DOI: 10.2147/IJNRD.S275721] [Reference Citation Analysis]
8 Sayan M, Arikan A, Sanlidag T. Comparison of Performance Characteristics of DxN VERIS System versus Qiagen PCR for HBV Genotype D and HCV Genotype 1b Quantification. Pol J Microbiol 2019;68:139-43. [PMID: 31050262 DOI: 10.21307/pjm-2019-008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Gras J, Mahjoub N, Charreau I, Cotte L, Tremblay C, Chas J, Raffi F, Cua E, Guillon B, Guigue N, Chaix ML, Meyer L, Molina JM, Delaugerre C; IPERGAY Study Group. Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis. AIDS 2020;34:47-52. [PMID: 31789889 DOI: 10.1097/QAD.0000000000002364] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
10 Ali ME, Halby HM, Ali MY, Hassan EA, El-Mokhtar MA, Sayed IM, Thabet MM, Fouad M, El-Ashmawy AM, Mahran ZG. Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. Viruses 2021;13:2008. [PMID: 34696438 DOI: 10.3390/v13102008] [Reference Citation Analysis]
11 Crowley D, Murtagh R, Cullen W, Keevans M, Laird E, McHugh T, McKiernan S, Miggin SJ, O'Connor E, O'Reilly D, Betts-Symonds G, Tobin C, Van Hout MC, Lambert JS. Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners. Harm Reduct J. 2019;16:42. [PMID: 31277665 DOI: 10.1186/s12954-019-0313-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
12 Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. Frontline Gastroenterol 2018;9:262-70. [PMID: 30245788 DOI: 10.1136/flgastro-2018-101017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
13 Vasanthakumar A, Davis JW, Abunimeh M, Söderholm J, Zha J, Dumas EO, Cohen DE, Waring JF, Lagging M. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS One 2018;13:e0198296. [PMID: 29851985 DOI: 10.1371/journal.pone.0198296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Elmowafy AY, El Maghrabi HM, Eldahshan KF, Refaie AF, Elbasiony MA, Matter YE, Saleh HH, Shiha GE, Rostaing L, Bakr MA. Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. Int Urol Nephrol 2019;51:1639-47. [PMID: 31363959 DOI: 10.1007/s11255-019-02246-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chen L, Du L, Kang S, Ma F, Li C, He M, Bai L, Tang H. Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Sci Rep 2021;11:11301. [PMID: 34050222 DOI: 10.1038/s41598-021-90706-5] [Reference Citation Analysis]
16 Kao JH, Lin CY, Chuang WL, Cheng YY, Hu JY, Liang WK, Friebe P, Palmer S, Huang CS. Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping. Diagn Microbiol Infect Dis 2019;94:344-8. [PMID: 30975461 DOI: 10.1016/j.diagmicrobio.2019.02.020] [Reference Citation Analysis]
17 Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 2017;9:E212. [PMID: 28783119 DOI: 10.3390/v9080212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
18 Mehta V, Mahajan R, Midha V, Narang V, Kaur K, Singh A, Malhotra A, Parvez A, Sood A. Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India. J Clin Exp Hepatol 2018;8:7-14. [PMID: 29743791 DOI: 10.1016/j.jceh.2017.06.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
19 Buggisch P, Heiken H, Mauss S, Weber B, Jung MC, Görne H, Heyne R, Hinrichsen H, Hidde D, König B, Pires Dos Santos AG, Niederau C, Berg T. Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study. PLoS One 2021;16:e0250833. [PMID: 33970940 DOI: 10.1371/journal.pone.0250833] [Reference Citation Analysis]
20 Trabut JB, Barrault C, Charlot H, Carmona D, Bourdel A, Benslimane M, François M, Kini-Matondo W, Causse R, Roudot-Thoraval F, Hézode C. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder. J Addict Med 2018;12:346-52. [PMID: 29702515 DOI: 10.1097/ADM.0000000000000415] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
21 Jülicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ 2018;21:1-10. [PMID: 28881157 DOI: 10.1080/13696998.2017.1369983] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
22 Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
23 El-sherif O, Jiang ZG, Tapper EB, Huang K, Zhong A, Osinusi A, Charlton M, Manns M, Afdhal NH, Mukamal K, Mchutchison J, Brainard DM, Terrault N, Curry MP. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 2018;154:2111-2121.e8. [DOI: 10.1053/j.gastro.2018.03.022] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 14.5] [Reference Citation Analysis]
24 Brancaccio G, Sorbo MC, Frigeri F, Rizzo V, Cantone M, Genderini F, Fabeni L, Pinto A, Perno CF, Ceccherini-Silberstein F, Gaeta GB. Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. Clin Gastroenterol Hepatol 2018;16:977-8. [PMID: 29104131 DOI: 10.1016/j.cgh.2017.10.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
25 McGowan DC, Khamlichi MD, De Groot A, Pauwels F, Delouvroy F, Van Emelen K, Simmen K, Raboisson P. Synthesis and evaluation of novel HCV replication inhibitors. Mol Divers 2017;21:475-81. [PMID: 28293834 DOI: 10.1007/s11030-017-9733-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Strazzulla A, Coppolino G, Barreca GS, Gentile I, Rivoli L, Postorino MC, Mazzitelli M, Greco G, Costa C, Pisani V, Marascio N, Simeoni M, Focà A, Fuiano G, Foti D, Gulletta E, Torti C. Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. Clin Mol Hepatol 2018;24:151-62. [PMID: 29684978 DOI: 10.3350/cmh.2017.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
27 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
28 Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep 2019;4:245-56. [PMID: 30775621 DOI: 10.1016/j.ekir.2018.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology 2020;71:1023-36. [PMID: 31365764 DOI: 10.1002/hep.30885] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
30 Simon KA, Flisiak R, Łapiński TW, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska KA, Piekarska A, Tronina O, Madej G, Garlicki A, Łucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski MS, Horban A, Knysz B, Tudrujek M, Halota W. Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study. Clin Exp Hepatol 2019;5:215-23. [PMID: 31598558 DOI: 10.5114/ceh.2019.87634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Vermehren J, Stelzl E, Maasoumy B, Michel-Treil V, Berkowski C, Marins EG, Paxinos EE, Marino E, Wedemeyer H, Sarrazin C, Kessler HH. Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. J Clin Microbiol 2017;55:1131-9. [PMID: 28122870 DOI: 10.1128/JCM.02193-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky J, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology & Hepatology 2018;3:125-33. [DOI: 10.1016/s2468-1253(17)30284-4] [Cited by in Crossref: 89] [Cited by in F6Publishing: 35] [Article Influence: 22.3] [Reference Citation Analysis]
33 Dussaq AM, Soni A, Willey C, Park SL, Harada S. Hepatitis C Virus Genie: A Web 2.0 Interpretation and Analytics Platform for the Versant Hepatitis C Virus Genotype Line Probe Assay Version 2.0. J Pathol Inform 2017;8:41. [PMID: 29114435 DOI: 10.4103/jpi.jpi_44_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Muratori P, Carbone M, Stangos G, Perini L, Lalanne C, Ronca V, Cazzagon N, Bianchi G, Lenzi M, Floreani A, Invernizzi P, Muratori L. Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Dig Liver Dis 2018;50:698-702. [PMID: 29567415 DOI: 10.1016/j.dld.2018.02.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
35 Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2018;67:1253-60. [PMID: 29152781 DOI: 10.1002/hep.29671] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 22.0] [Reference Citation Analysis]
36 Kurniawan J, Gani RA, Hasan I, Sulaiman AS, Lesmana CRA, Jasirwan COM, Kalista KF, Nababan SHH, Zulkifly S. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability. Indian J Gastroenterol 2018;37:520-5. [PMID: 30637537 DOI: 10.1007/s12664-018-0921-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
38 Weigert A, Querido S, Carvalho L, Lebre L, Chagas C, Matias P, Birne R, Nascimento C, Jorge C, Adragão T, Bruges M, Machado D. Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal. Transplant Proc 2018;50:743-5. [PMID: 29661427 DOI: 10.1016/j.transproceed.2018.02.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort. World J Gastroenterol 2018; 24(7): 852-861 [PMID: 29467555 DOI: 10.3748/wjg.v24.i7.852] [Reference Citation Analysis]
40 Zarębska-Michaluk D, Buczyńska I, Simon K, Tudrujek-Zdunek M, Janczewska E, Dybowska D, Sitko M, Dobracka B, Jaroszewicz J, Pabjan P, Klapaczyński J, Laurans Ł, Mazur W, Socha Ł, Tronina O, Parczewski M, Flisiak R. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Can J Gastroenterol Hepatol 2019;2019:4029541. [PMID: 30941326 DOI: 10.1155/2019/4029541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
41 Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc ÖM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, Peerlinck K, Apers L, Robaeys G, Lazarus JV. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis 2020;20:181. [PMID: 32106819 DOI: 10.1186/s12879-020-4898-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
42 Kawano A, Shigematsu H, Miki K, Ichiki Y, Morita C, Yanagita K, Takahashi K, Dohmen K, Nomura H, Ishibashi H, Shimoda S. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. Intern Med 2018;57:1533-42. [PMID: 29321441 DOI: 10.2169/internalmedicine.9857-17] [Reference Citation Analysis]
43 Valdez-Hernández P, Rodríguez-Aguilar EF, Páez-Zayas VM, Lizárraga-Gómez E, García-Juárez I. [Proposal for a simple scheme of direct-action antivirals for HCV treatment in a low budget public health system]. Salud Publica Mex 2018;60:738-40. [PMID: 30699280 DOI: 10.21149/9492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Miotto N, Mendes LC, Zanaga LP, Lazarini MSK, Goncales ESL, Pedro MN, Goncales FL Jr, Stucchi RSB, Vigani AG. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS One 2018;13:e0199941. [PMID: 29990371 DOI: 10.1371/journal.pone.0199941] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
45 George J, Burnevich E, Sheen IS, Heo J, Kinh NV, Tanwandee T, Cheng PN, Kim DY, Tak WY, Kizhlo S, Zhdanov K, Isakov V, Liang L, Lindore P, Ginanni J, Nguyen BY, Wahl J, Barr E, Robertson M, Ingravallo P, Talwani R; C‐CORAL Study Investigators. Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. Hepatol Commun 2018;2:595-606. [PMID: 29761174 DOI: 10.1002/hep4.1177] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
46 Abadía M, Montes ML, Ponce D, Froilán C, Romero M, Poza J, Hernández T, Fernández-Martos R, Olveira A, on behalf of the “La Paz Portal Hypertension” Study Group Investigators. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis. World J Gastroenterol 2019; 25(21): 2665-2674 [PMID: 31210717 DOI: 10.3748/wjg.v25.i21.2665] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
47 Perpiñán E, Caro-Pérez N, García-González N, Gregori J, González P, Bartres C, Soria ME, Perales C, Lens S, Mariño Z, Londoño MC, Ariza X, Koutsoudakis G, Quer J, González-Candelas F, Forns X, Pérez-Del-Pulgar S. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. J Viral Hepat 2018;25:1515-25. [PMID: 30141252 DOI: 10.1111/jvh.12986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
48 Murtagh R, Swan D, O'Connor E, McCombe G, Lambert JS, Avramovic G, Cullen W. Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study. Interact J Med Res 2018;7:e10313. [PMID: 30567692 DOI: 10.2196/10313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med 2019;10:323-34. [PMID: 31572038 DOI: 10.2147/JBM.S186362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
50 Mauro E, Crespo G, Montironi C, Londoño M, Hernández-gea V, Ruiz P, Sastre L, Lombardo J, Mariño Z, Díaz A, Colmenero J, Rimola A, Garcia-pagán JC, Brunet M, Forns X, Navasa M. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C: Mauro et al. Hepatology 2018;67:1683-94. [DOI: 10.1002/hep.29557] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 16.5] [Reference Citation Analysis]
51 Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One 2019;14:e0225061. [PMID: 31714950 DOI: 10.1371/journal.pone.0225061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Szymanek-Pasternak A, Rostkowska K, Simon K. Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. BMJ Case Rep 2017;2017:bcr-2017-220152. [PMID: 28918403 DOI: 10.1136/bcr-2017-220152] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
53 Venugopal V, Padmanabhan P, Raja R, Dixit NM. Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection. PLoS Comput Biol 2018;14:e1006335. [PMID: 30001324 DOI: 10.1371/journal.pcbi.1006335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP. Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy. Journal of Hepatology 2017;66:862-3. [DOI: 10.1016/j.jhep.2017.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
55 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
56 Schmidt-Martin D, Elsharkawy AM. Editorial: is ribavirin needed in the treatment of post-transplant hepatitis C recurrence? Aliment Pharmacol Ther 2017;46:197-8. [PMID: 28621075 DOI: 10.1111/apt.14110] [Reference Citation Analysis]
57 Xiao H, Chen J, Wang J, Li J, Yang F, Lu H. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine (Baltimore) 2019;98:e16524. [PMID: 31348267 DOI: 10.1097/MD.0000000000016524] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63. [PMID: 29098647 DOI: 10.1007/s15010-017-1093-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
59 Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Arch Dis Child. 2017;102:668-671. [PMID: 28473309 DOI: 10.1136/archdischild-2017-312708] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
60 Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684 [PMID: 30386460 DOI: 10.4254/wjh.v10.i10.670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
61 Gayam V, Khalid M, Mandal AK, Hussain MR, Mukhtar O, Gill A, Garlapati P, Shrestha B, Guss D, Sherigar J, Mansour M, Mohanty S. Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting. Gastroenterology Res 2018;11:130-7. [PMID: 29707080 DOI: 10.14740/gr999w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
62 Galli C, Julicher P, Plebani M. HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection. Clin Chem Lab Med 2018;56:880-8. [PMID: 29702484 DOI: 10.1515/cclm-2017-0754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
63 Calleja JL, Bermúdez Á, Camacho Á, Cárdenas F, Fernández S, de Juan J, Jorquera F, Linares M, Rodríguez MÁ, Romero M, Ruiz JJ, José Sánchez M, de la Vega J. Optimisation in the multidisciplinary approach to patients with hepatitis C in the era of direct-acting antivirals. Gastroenterol Hepatol 2019;42 Suppl 1:8-13. [PMID: 32560771 DOI: 10.1016/S0210-5705(20)30182-5] [Reference Citation Analysis]
64 Donato MF, Morelli C, Romagnoli R, Invernizzi F, Mazzarelli C, Iemmolo RM, Montalbano M, Lenci I, Bhoori S, Pieri G, Berardi S, Caraceni P, Martini S; ITACOPS-SOF Bridging Study Group. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. Liver Int 2017;37:678-83. [PMID: 27865034 DOI: 10.1111/liv.13322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
65 Kim KA, Lee JS. Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey. Gut Liver 2020;14:644-51. [PMID: 31842525 DOI: 10.5009/gnl19272] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Merat S, Sharifi AH, Haj-sheykholeslami A, Poustchi H, Fattahi B, Nateghi-baygi A, Alavian SM, Malekzadeh R. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3. Hepat Mon 2016;17. [DOI: 10.5812/hepatmon.44564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
67 Azeem HA, Alkabeer AM, Mohammed AS, Hussein AA. Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs). Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00121-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Morimoto N, Miura K, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Murayama K, Hirosawa T, Goka R, Kunitomo N, Nakamura H, Sugimoto H, Isoda N, Yamamoto H. Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment. J Rural Med 2019;14:78-86. [PMID: 31191770 DOI: 10.2185/jrm.2993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Mendizabal M, Haddad L, Gallardo PE, Ferrada A, Soza AA, Adrover R, Aravena E, Roblero JP, Prieto J, Vujacich C, Romero G, Muñoz A, Anders M, Hernández N, Coccozella D, Gruz F, Reggiardo MV, Ruf AE, Varón A, Cartier M, Pérez Ravier R, Ridruejo E, Peralta M, Poncino D, Vorobioff J, Aballay Soteras G, Silva MO. Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America. J Med Virol 2017;89:1590-6. [DOI: 10.1002/jmv.24816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
70 Taibi C, Tempestilli M, D'Avolio A, Garbuglia AR, De Nicolò A, Montalbano M, D'Offizi G. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. J Clin Pharm Ther 2017;42:621-3. [PMID: 28474408 DOI: 10.1111/jcpt.12546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
71 Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Review of Molecular Diagnostics 2017;17:1109-15. [DOI: 10.1080/14737159.2017.1400385] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 15.0] [Reference Citation Analysis]
72 Uribe-Noguez LA, Ocaña-Mondragón A, Mata-Marín JA, Cázares-Cortázar A, Ribas-Aparicio RM, Gómez-Torres ME, Gaytán-Martínez J, Martínez-Rodríguez ML. Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir. J Infect Chemother 2018;24:928-31. [PMID: 29773440 DOI: 10.1016/j.jiac.2018.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
73 da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. J Hepatol 2017;67:1348-50. [PMID: 28789880 DOI: 10.1016/j.jhep.2017.06.035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
74 Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol 2017;178:130-6. [PMID: 28439915 DOI: 10.1111/bjh.14640] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
75 Solas C, Bregigeon S, Faucher-Zaegel O, Quaranta S, Obry-Roguet V, Tamalet C, Lacarelle B, Poizot-Martin I. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety. Br J Clin Pharmacol 2018;84:404-9. [PMID: 29028125 DOI: 10.1111/bcp.13450] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
76 Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open 2019;9:e029066. [PMID: 31383704 DOI: 10.1136/bmjopen-2019-029066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology 2019;69:2349-63. [PMID: 30693573 DOI: 10.1002/hep.30527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
78 De Paschale M, Manco MT, Arpino O, Ricucci V, Paganini A, Belvisi L, Cagnin D, Cerulli T, Cianflone A, Agrappi C, Mirri P, Clerici P. Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results. J Med Virol 2017;89:1817-22. [PMID: 28401710 DOI: 10.1002/jmv.24831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
79 Gubay F, Staunton R, Metzig C, Abubakar I, White PJ. Assessing uncertainty in the burden of hepatitis C virus: Comparison of estimated disease burden and treatment costs in the UK. J Viral Hepat 2018;25:514-23. [PMID: 29274178 DOI: 10.1111/jvh.12847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
80 Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res 2020;12:5323-30. [PMID: 32753950 DOI: 10.2147/CMAR.S254580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Yang R, Wei L. Profile of the VERSANT HCV genotype 2.0 assay. Expert Rev Mol Diagn 2018;18:995-1004. [PMID: 30372355 DOI: 10.1080/14737159.2018.1541740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
82 Kamel S, Elessawy H, Ashraf O, Elbaz A, Dabbous H, El-sayed M, Ali S, Kamel H. Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients. Gastroenterology Insights 2021;12:336-46. [DOI: 10.3390/gastroent12030031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Degasperi E, Aghemo A, Paolucci S, D'Ambrosio R, Borghi M, Perbellini R, Novazzi F, De Nicola S, Lunghi G, Baldanti F, Lampertico P. 12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. Dig Liver Dis 2018;50:703-6. [PMID: 29499903 DOI: 10.1016/j.dld.2018.02.003] [Reference Citation Analysis]
84 Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int 2018;2018:3140983. [PMID: 29546055 DOI: 10.1155/2018/3140983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
85 Lazarus JV, Stumo SR, Harris M, Hendrickx G, Hetherington KL, Maticic M, Jauffret-Roustide M, Tallada J, Simojoki K, Reic T, Safreed-Harmon K; Hep-CORE Study Group. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. J Int AIDS Soc 2018;21 Suppl 2:e25052. [PMID: 29633562 DOI: 10.1002/jia2.25052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
86 Akar T. Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C? Rev Assoc Med Bras (1992) 2018;64:224-9. [PMID: 29641775 DOI: 10.1590/1806-9282.64.03.224] [Reference Citation Analysis]
87 Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect 2018;24:308.e5-8. [PMID: 28811242 DOI: 10.1016/j.cmi.2017.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
88 Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C. Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Euro Surveill 2017;22:30582. [PMID: 28797326 DOI: 10.2807/1560-7917.ES.2017.22.30.30582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
89 Padhi S, Maharshi S, Gupta GK, Garg K, Nijhawan S. Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children. J Pediatr Hematol Oncol. 2018;40:511-514. [PMID: 29771862 DOI: 10.1097/mph.0000000000001217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
90 Osawa M, Ueno T, Shiozaki T, Ishikawa H, Li H, Garimella T. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. Clin Pharmacol Drug Dev 2019;8:802-17. [PMID: 30629858 DOI: 10.1002/cpdd.649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
91 Artemova MG, Abdurakhmanov DT. [Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects]. Ter Arkh 2017;89:110-4. [PMID: 28514410 DOI: 10.17116/terarkh2017894110-114] [Reference Citation Analysis]
92 Wahab MA, Shehta A, Elshoubary M, Yassen AM, Elmorshedi M, Salah T, Sultan AM, Fathy O, Elsarraf WR, Shiha U, Zalata K, Elghawalby AN, Eldesoky M, Monier A, Said R, Elsabagh AM, Ali M, Kandeel A, Abdalla U, Aboelella M, Elsadany M, Abdel-Khalek EE, Marwan A, ElMorsi FM, Adly R. Living-Donor Liver Transplantation in Hepatitis C Virus Era: A Report of 500 Consecutive Cases in a Single Center. Transplant Proc 2018;50:1396-406. [PMID: 29880362 DOI: 10.1016/j.transproceed.2018.02.085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
93 Steiner S, Raguž-lučić N, Erceg D. Direct-Acting Antivirals (DAAs): Drug-Drug Interactions (DDIs) in the Treatment of Hepatitis C Virus (HCV). In: Smolic M, Vcev A, Wu GY, editors. Update on Hepatitis C. InTech; 2017. [DOI: 10.5772/intechopen.70788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
94 Huang Y, Li MH, Hou M, Xie Y. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int 2017;16:470-9. [PMID: 28992878 DOI: 10.1016/S1499-3872(17)60044-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
95 Li C, Hu J. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection. Medicine (Baltimore) 2018;97:e0416. [PMID: 29642211 DOI: 10.1097/MD.0000000000010416] [Reference Citation Analysis]
96 Alsebaey A, Elhelbawy M, Abdel-Razek W, Hashim M, Elshenawy H, Waked I. HCV treatment with direct acting antivirals improves the insulin sensitivity. Expert Rev Anti Infect Ther. 2019;17:749-754. [PMID: 31393188 DOI: 10.1080/14787210.2019.1653184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
97 De Nicola S, Colombo M. Antiviral treatment of hepatitis C in renal transplant patients - safety issues. Expert Opin Drug Saf 2017;16:873-6. [PMID: 28636836 DOI: 10.1080/14740338.2017.1344640] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Caballero-Marcos A, Romero-Cristóbal M, Puerto M, Fernández-Yunquera A, Dieguez L, Navarrete C, Clemente A, Diaz-Fontenla F, Catalán P, Rincón D, López-Baena JÁ, Bañares Cañizares R, Salcedo M. HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation. Transpl Int 2021. [PMID: 34346111 DOI: 10.1111/tri.14000] [Reference Citation Analysis]
99 Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol 2019;70:15-23. [PMID: 30266283 DOI: 10.1016/j.jhep.2018.09.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
100 Vermehren J, Bourlière M, Pol S, Marcellin P, Hyland RH, Jiang D, Brainard DM, Zeuzem S, Welzel TM. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. J Clin Virol 2017;89:51-6. [PMID: 28259054 DOI: 10.1016/j.jcv.2017.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
101 Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
102 Dzobo K. The Role of Viruses in Carcinogenesis and Molecular Targeting: From Infection to Being a Component of the Tumor Microenvironment. OMICS 2021;25:358-71. [PMID: 34037476 DOI: 10.1089/omi.2021.0052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Huang W, Wang M, Gong Q, Yu D, Chen P, Lin J, Han Y, Su Y, Qu L, Zhang X. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. Microb Drug Resist. 2019;. [PMID: 30702389 DOI: 10.1089/mdr.2018.0360] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
104 Suhail M, Sohrab SS, Qureshi A, Tarique M, Abdel-Hafiz H, Al-Ghamdi K, Qadri I. Association of HCV mutated proteins and host SNPs in the development of hepatocellular carcinoma. Infect Genet Evol 2018;60:160-72. [PMID: 29501636 DOI: 10.1016/j.meegid.2018.02.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
105 Mohazzab-torabi S, Dolatimehr F, Sharafi H, Safi-abadi M, Rezaee-zavareh MS, Bayatpour E, Karimi-sari H, Alavian SM. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.82971] [Reference Citation Analysis]
106 Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother 2018;62:e01620-17. [PMID: 29084747 DOI: 10.1128/AAC.01620-17] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
107 Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J 2019;16:32. [PMID: 31072401 DOI: 10.1186/s12954-019-0303-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
108 Lampejo T, Agarwal K, Carey I. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. Dig Liver Dis 2018;50:113-23. [PMID: 29233687 DOI: 10.1016/j.dld.2017.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
109 Orita N, Shimakami T, Sunagozaka H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Takatori H, Kawaguchi K, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clin J Gastroenterol 2019;12:63-70. [PMID: 29995231 DOI: 10.1007/s12328-018-0884-y] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
110 Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, Czubkowski P, Gupte G, Mozer-Glassberg Y, van der Woerd W, Smets F, Verkade HJ, Fischler B. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:505-515. [PMID: 29287014 DOI: 10.1097/mpg.0000000000001872] [Cited by in Crossref: 58] [Cited by in F6Publishing: 20] [Article Influence: 19.3] [Reference Citation Analysis]
111 Nagaty A, Abd El-Wahab EW. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One 2017;12:e0184654. [PMID: 28981513 DOI: 10.1371/journal.pone.0184654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
112 Taramasso L, Di Biagio A, Bovis F, Nicolini LA, Antinori A, Milazzo L, Sollima S, Gubertini G, Niero F, Saracino A, Bruno R, Borghi V, Montagnani F, Cattelan A, Hasson H, Taliani G, D'Arminio Monforte A, Mastroianni C, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Cacopardo B, Giacometti A, Parruti G, Vullo V, Chirianni A, Teti E, Pasquazzi C, Segala D, Andreoni M. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One 2018;13:e0192627. [PMID: 29462201 DOI: 10.1371/journal.pone.0192627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
113 Somerville L, Doucette K. Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation. Curr Infect Dis Rep 2018;20:18. [PMID: 29789956 DOI: 10.1007/s11908-018-0625-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
114 Ponti ML, Comitini F, Murgia D, Ganga R, Canu R, Dessì C, Foschini ML, Leoni G, Morittu M, Perra M, Pilia MP, Casini MR, Zappu A, Origa R. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major. Dig Liver Dis 2019;51:561-7. [PMID: 30658940 DOI: 10.1016/j.dld.2018.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
115 Nouhin J, Bollore K, Castera-Guy J, Prak S, Heng S, Kerleguer A, Rubbo PA, Rouet F, Tuaillon E. Analytical and field evaluation of the Biocentric Generic HCV assay on open polyvalent PCR platforms in France and Cambodia. J Clin Virol 2018;108:53-8. [PMID: 30245364 DOI: 10.1016/j.jcv.2018.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Hwang JP, Torres HA. Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. Curr Opin Infect Dis 2018;31:535-41. [PMID: 30299355 DOI: 10.1097/QCO.0000000000000500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Gane E, Nahass R, Luketic V, Asante-Appiah E, Hwang P, Robertson M, Wahl J, Barr E, Haber B. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. J Viral Hepat 2017;24:895-9. [PMID: 28470815 DOI: 10.1111/jvh.12719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
118 Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J, Sockalingam S, Altenberg J, Powis J. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. International Journal of Drug Policy 2017;47:202-8. [DOI: 10.1016/j.drugpo.2017.05.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 13.6] [Reference Citation Analysis]
119 Ford JS, Chechi T, Toosi K, Mahmood B, Meehleis D, Otmar M, Tran N, May L. Universal Screening for Hepatitis C Virus in the ED Using a Best Practice Advisory. West J Emerg Med 2021;22:719-25. [PMID: 34125052 DOI: 10.5811/westjem.2021.1.49667] [Reference Citation Analysis]
120 Kyuregyan KK, Malinnikova EY, Soboleva NV, Isaeva OV, Karlsen AA, Kichatova VS, Potemkin IA, Schibrik EV, Gadjieva OA, Bashiryan BA, Lebedeva NN, Serkov IL, Yankina A, Galli C, Mikhailov MI. Community screening for hepatitis C virus infection in a low-prevalence population. BMC Public Health 2019;19:1038. [PMID: 31375104 DOI: 10.1186/s12889-019-7388-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
121 Sharma S, Mukherjee D, Nair RK, Datt B, Rao A. Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients. J Transplant 2018;2018:7579689. [PMID: 29796311 DOI: 10.1155/2018/7579689] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
122 Lee BS, Song MJ, Kwon JH, Lee TH, Jang JW, Kim SH, Lee SH, Kim HS, Kim JH, Kim SB, Ko SY, Song DS. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis. Gut Liver 2019;13:191-6. [PMID: 30400729 DOI: 10.5009/gnl18240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Santoriello D, Pullela NK, Uday KA, Dhupar S, Radhakrishnan J, D'Agati VD, Markowitz GS. Persistent Hepatitis C Virus-Associated Cryoglobulinemic Glomerulonephritis in Patients Successfully Treated With Direct-Acting Antiviral Therapy. Kidney Int Rep 2018;3:985-90. [PMID: 29988995 DOI: 10.1016/j.ekir.2018.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
124 Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, Bonet L, Ryan P, Gea F, Díaz-Sánchez A, García-Mayor M, Martín-Carbonero L, Castillo P, Manzano ML, González-Moreno L, Pulido F, Gutiérrez ML, Moreno JM, García-Amengual IM, Cuevas G, Guerrero A, Rivero-Fernández M, Portales ME, Montes ML, Olveira A. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. Liver Int 2021;41:2885-91. [PMID: 34392590 DOI: 10.1111/liv.15032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 El-Shabrawi MH, Abdo AM, El-Khayat HR, Yakoot M. Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2018;66:425-427. [PMID: 29135824 DOI: 10.1097/mpg.0000000000001838] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 6.7] [Reference Citation Analysis]
126 Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective. Harm Reduct J. 2018;15:62. [PMID: 30538000 DOI: 10.1186/s12954-018-0269-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
127 Guzman Ramos MI, Manzano-García M, Robustillo-Cortés MLA, Pineda JA, Morillo-Verdugo R. Effect on the adherence to concomitant medications after initiation of treatment with direct-acting antiviral agents against hepatitis C virus. Gastroenterol Hepatol 2020;43:418-25. [PMID: 32279937 DOI: 10.1016/j.gastrohep.2020.02.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 El-Tahan RR, Ghoneim AM, Zaghloul H. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients. Virus Genes 2020;56:564-81. [PMID: 32572756 DOI: 10.1007/s11262-020-01776-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 El Kassas M, Shimakawa Y, Ali-Eldin Z, Funk AL, Wifi MN, Zaky S, El-Raey F, Esmat G, Fontanet A. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int 2018;38:2159-69. [PMID: 29738637 DOI: 10.1111/liv.13874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
130 Invernizzi F, Colombo M. Pathway of care of hepatocellular carcinoma in 2017. Hepat Oncol 2016;3:217-21. [PMID: 30191044 DOI: 10.2217/hep-2017-0004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
131 Crowley D, Lambert JS, Betts-Symonds G, Cullen W, Keevans M, Kelly E, Laird E, McHugh T, McKiernan S, Miggin SJ, Murphy C, Murtagh R, O'Reilly D, Tobin C, Van Hout MC. The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017. Euro Surveill 2019;24. [PMID: 30968825 DOI: 10.2807/1560-7917.ES.2019.24.14.1800369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
132 Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang KW, Lagging M. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. J Virol 2018;92:e01087-18. [PMID: 30045981 DOI: 10.1128/JVI.01087-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
133 Cunha-Silva M, Mazo D, Arrelaro R, Vaz N, Rabello M, Lopes T, Corrêa B, Torino AB, Cintra M, Lorena S, Sevá-Pereira T, Almeida J. Hand-foot syndrome due to hepatitis C therapy. Rev Assoc Med Bras (1992) 2018;64:415-9. [PMID: 30304139 DOI: 10.1590/1806-9282.64.05.415] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
134 Gupta S, Rout G, Patel AH, Mahanta M, Kalra N, Sahu P, Sethia R, Agarwal A, Ranjan G, Kedia S, Acharya SK, Nayak B, Shalimar. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection. J Viral Hepat 2018;25:771-8. [DOI: 10.1111/jvh.12870] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
135 Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int. 2018; Epub ahead of print. [PMID: 29461687 DOI: 10.1111/liv.13727] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
136 Braun DL, Hampel B, Kouyos R, Nguyen H, Shah C, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-heule P, Nicca D, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Böni J, Fehr JS, Anagnostopoulos A, Battegay M, B E, B J, B DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, F JS, Fellay J, Furrer H, Fux CA, G HF, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Kahlert C, Kaiser L, Keiser O, Klimkait T, K R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, N D, Paioni P, Pantaleo G, Perreau M, R A, Rudin C, Scherrer AU, S P, Speck R, S M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S; Swiss HIV Cohort Study. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Men Who Have Sex With Men. Clinical Infectious Diseases 2019;68:569-76. [DOI: 10.1093/cid/ciy547] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
137 Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants. Gastroenterology. 2018;154:1435-1448. [PMID: 29274866 DOI: 10.1053/j.gastro.2017.12.015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
138 Said M, Omar H, Soliman Z, Saad Y, Dabes H, Hamed S, ElSaeed K, ElShazly Y, ElSerafy M. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort. Expert Rev Gastroenterol Hepatol 2019;13:89-93. [PMID: 30791838 DOI: 10.1080/17474124.2019.1544070] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PLoS One 2020;15:e0229517. [PMID: 32106270 DOI: 10.1371/journal.pone.0229517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
140 de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Clin Infect Dis 2018;66:1013-8. [PMID: 29077864 DOI: 10.1093/cid/cix916] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
141 El Raziky M, Zayed NA, Abdel Baki A, Mansour SA, Shahin RMH. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. J Med Virol 2017;89:1823-9. [PMID: 28480960 DOI: 10.1002/jmv.24844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
142 Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. PLoS One 2018;13:e0197544. [PMID: 29874250 DOI: 10.1371/journal.pone.0197544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
143 Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. Clin Exp Hepatol 2020;6:163-9. [PMID: 33145422 DOI: 10.5114/ceh.2020.98606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
144 Jülicher P, Chulanov VP, Pimenov NN, Chirkova E, Yankina A, Galli C. Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis. PLoS One 2019;14:e0219687. [PMID: 31310636 DOI: 10.1371/journal.pone.0219687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
145 Sarwar S, Tarique S, Aleem A, Khan AA. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. Eur J Gastroenterol Hepatol 2019;31:1035-9. [PMID: 31274596 DOI: 10.1097/MEG.0000000000001376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
146 Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opin Investig Drugs 2018;27:243-50. [PMID: 29271672 DOI: 10.1080/13543784.2018.1420780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
147 Saludes V, Antuori A, Reinhardt B, Viciana I, Clavijo E, Schreiber L, Tenenbaum M, Rodriguez-Frias F, Quer J, Matas L, Martró E. Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay. Sci Rep 2019;9:3678. [PMID: 30842623 DOI: 10.1038/s41598-019-40099-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
148 Llovet LP, Sciarrone S, Rodríguez-Tajes S, Montironi C, Mescoli C, Rugge M, Crespo G, Burra P, Forns X, Diaz A, Londoño MC. Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. Gastroenterol Hepatol 2020;43:14-21. [PMID: 31495536 DOI: 10.1016/j.gastrohep.2019.07.006] [Reference Citation Analysis]
149 Araújo RC, Dias FC, Bertol BC, Silva DM, Almeida PH, Teixeira AC, Souza FF, Villanova MG, Ramalho LNZ, Donadi EA, Martinelli ALC. Liver HLA-E Expression Is Associated with Severity of Liver Disease in Chronic Hepatitis C. J Immunol Res 2018;2018:2563563. [PMID: 29951556 DOI: 10.1155/2018/2563563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
150 Teng W, Jeng WJ, Yang HI, Chen WT, Hsieh YC, Huang CH, Lin CC, Lin CY, Lin SM, Sheen IS. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2019;12:E23. [PMID: 31861706 DOI: 10.3390/cancers12010023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
151 Eletreby R, El-Serafy M, Anees M, Kasem G, Salama M, Elkhouly R, Hamdy M, Abdel Haleem H, Kamal E, Abdel-Razek W, Salama R, Elshenawy M, Shafeek A, Hassany M, El-Sayed MH, El-Shazly Y, Esmat G. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int 2020;40:797-805. [PMID: 31858694 DOI: 10.1111/liv.14299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
152 Crismale JF, Ahmad J. Expanding treatment for hepatitis C in Canada. CMAJ 2018;190:E667-8. [PMID: 29866891 DOI: 10.1503/cmaj.170931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol 2019;15:73-86. [DOI: 10.1038/s41581-018-0081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
154 Malsagova KA, Pleshakova TO, Galiullin RA, Shumov ID, Kozlov AF, Romanova TS, Popov VP, Glukhov AV, Konev VA, Archakov AI, Ivanov YD. Nanowire Aptamer-Sensitized Biosensor Chips with Gas Plasma-Treated Surface for the Detection of Hepatitis C Virus Core Antigen. Coatings 2020;10:753. [DOI: 10.3390/coatings10080753] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 6.5] [Reference Citation Analysis]
155 Liao HT, Tan P, Huang JW, Yuan KF. Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis. Transplant Proc 2017;49:1855-63. [PMID: 28923637 DOI: 10.1016/j.transproceed.2017.04.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
156 Nafari M, Irani S, Vaziri F, Gharibzadeh S, Sakhaee F, Khazeni M, Kalhor N, Jamnani FR, Siadat SD, Fateh A. Correlation of CD81 and SCARB1 polymorphisms on virological responses in Iranian patients with chronic hepatitis C virus genotype 1. Infect Genet Evol 2018;62:296-303. [PMID: 29715527 DOI: 10.1016/j.meegid.2018.04.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 van der Helm D, Groenewoud A, de Jonge-Muller ESM, Barnhoorn MC, Schoonderwoerd MJA, Coenraad MJ, Hawinkels LJAC, Snaar-Jagalska BE, van Hoek B, Verspaget HW. Mesenchymal stromal cells prevent progression of liver fibrosis in a novel zebrafish embryo model. Sci Rep 2018;8:16005. [PMID: 30375438 DOI: 10.1038/s41598-018-34351-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
158 Dimitroglou J, Zampetas D, Vasilieva L, Koullias E, Ketikoglou I, Alexopoulou A, Dourakis SP. Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals. Aliment Pharmacol Ther 2017;46:908-9. [PMID: 29023878 DOI: 10.1111/apt.14276] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
159 Yang CHT, Goel A, Ahmed A. Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. Adolesc Health Med Ther 2018;9:103-10. [PMID: 30104913 DOI: 10.2147/AHMT.S147896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Calvaruso V, Craxì A. HBV recurrence after HCV clearance on DAAs: Sometimes they come back. J Hepatol 2017;67:898-901. [PMID: 28864279 DOI: 10.1016/j.jhep.2017.08.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
161 Lei JH, Liang J, Gong X, Xiao XQ, Chen Z, Peng F. Analysis of Transmission Routes of Hepatitis C Virus Based on Virus Genotyping in 341 Cases with Different Suspected Initial Infection Time Points in Hunan Province, China. Med Sci Monit 2018;24:5232-41. [PMID: 30055000 DOI: 10.12659/MSM.907424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
162 Bruno G, Saracino A, Fabrizio C, Scudeller L, Milano E, Dell'Acqua R, Ladisa N, Fasano M, Minniti S, Buccoliero G, Tartaglia A, Giammario A, Milella M, Angarano G. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. Int J Antimicrob Agents 2017;49:296-301. [PMID: 28163136 DOI: 10.1016/j.ijantimicag.2016.11.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
163 Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag 2017;13:733-8. [PMID: 28790832 DOI: 10.2147/TCRM.S133983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
164 Niebel M, Singer JB, Nickbakhsh S, Gifford RJ, Thomson EC. Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination? Lancet Gastroenterol Hepatol 2017;2:700-1. [PMID: 28895545 DOI: 10.1016/S2468-1253(17)30257-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
165 Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults. Expert Opinion on Pharmacotherapy 2017;19:49-64. [DOI: 10.1080/14656566.2017.1419185] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
166 Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, Karlberg J, Lau G. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017;66:13-26. [PMID: 28195337 DOI: 10.1002/hep.29109] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 19.2] [Reference Citation Analysis]
167 Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
168 Zampino R, Vitrone M, Parrella A, Ragone E, Durante-Mangoni E. Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases. J Chemother 2018;30:129-30. [PMID: 28925824 DOI: 10.1080/1120009X.2017.1376782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
169 Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ;  SIMPLIFY Study Group. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:153-161. [PMID: 29310928 DOI: 10.1016/s2468-1253(17)30404-1] [Cited by in Crossref: 135] [Cited by in F6Publishing: 63] [Article Influence: 33.8] [Reference Citation Analysis]
170 Mate-Cano I, Alvaro-Meca A, Ryan P, Resino S, Briz V. Epidemiological trend of hepatitis C-related liver events in Spain (2000-2015): A nationwide population-based study. Eur J Intern Med 2020;75:84-92. [PMID: 32143898 DOI: 10.1016/j.ejim.2020.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52. [PMID: 28288626 DOI: 10.1186/s12916-017-0815-7] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 17.4] [Reference Citation Analysis]
172 Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514-528. [PMID: 28105744 DOI: 10.1111/liv.13327] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
173 El Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi MN, Youssef N, Ezzat S, Tahoon M, Abdelsalam L, Abdelhakam SM, Ali-Eldin Z. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med 2019;10:295-302. [PMID: 34652758 DOI: 10.1007/s41999-019-00167-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Zhan Z, Chen Y, Duan Y, Li L, Mew K, Hu P, Ren H, Peng M. Identification of key genes, pathways and potential therapeutic agents for liver fibrosis using an integrated bioinformatics analysis. PeerJ 2019;7:e6645. [PMID: 30923657 DOI: 10.7717/peerj.6645] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
175 Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV; Hep-Nordic Study Group. Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS One 2018;13:e0190146. [PMID: 29381697 DOI: 10.1371/journal.pone.0190146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
176 Shin J, Yu JH, Jin YJ, Chae MH, Yoon CH, Lee JW. Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. Medicine (Baltimore) 2019;98:e18020. [PMID: 31764818 DOI: 10.1097/MD.0000000000018020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Lieber SR, Fried MW. Controversies in hepatitis C therapy: Reactivation of hepatitis B virus. Clin Liver Dis (Hoboken) 2017;10:87-92. [PMID: 31186893 DOI: 10.1002/cld.665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
178 Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. J Viral Hepat 2018;25:1180-8. [DOI: 10.1111/jvh.12917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
179 Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol 2018;31:35-41. [PMID: 29333065 DOI: 10.20524/aog.2017.0204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
180 Sølund C, Andersen ES, Mössner B, Laursen AL, Røge BT, Kjær MS, Gerstoft J, Christensen PB, Pedersen MS, Schønning K, Fahnøe U, Bukh J, Weis N. Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study. Eur J Gastroenterol Hepatol 2018;30:1177-86. [PMID: 29994874 DOI: 10.1097/MEG.0000000000001192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
181 Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatol Commun 2018;2:1274-83. [PMID: 30288480 DOI: 10.1002/hep4.1246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
182 Lydié N, Saboni L, Gautier A, Brouard C, Chevaliez S, Barin F, Larsen C, Lot F, Rahib D. Innovative Approach for Enhancing Testing of HIV, Hepatitis B, and Hepatitis C in the General Population: Protocol for an Acceptability and Feasibility Study (BaroTest 2016). JMIR Res Protoc 2018;7:e180. [PMID: 30314963 DOI: 10.2196/resprot.9797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
183 Bradley-Stewart A, Goldstein E, MacLean A, Gunson R. Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland. J Clin Virol 2018;101:44-6. [PMID: 29414187 DOI: 10.1016/j.jcv.2018.01.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
184 Mazzola G, Adamoli L, Calvaruso V, Macaluso FS, Colletti P, Mazzola S, Cervo A, Trizzino M, Di Lorenzo F, Iaria C, Prestileo T, Orlando A, Di Marco V, Cascio A. Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. Infection 2019;47:409-15. [PMID: 30519966 DOI: 10.1007/s15010-018-1258-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
185 Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology 2017;66:1814-25. [PMID: 28741307 DOI: 10.1002/hep.29399] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
186 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 90.0] [Reference Citation Analysis]
187 Yoneyama H, Morishita A, Iwama H, Fujita K, Masaki T, Tani J, Tadokoro T, Nomura T, Sakamoto T, Oura K, Takuma K, Nakahara M, Mimura S, Deguchi A, Oryu M, Tsutsui K, Himoto T, Shimotohno K, Wakita T, Kobara H, Masaki T. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies. J Gastroenterol Hepatol 2021;36:1126-35. [PMID: 32839985 DOI: 10.1111/jgh.15224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Ahmed M, Mansey AE, Wahsh EA, Gomaa AA, Rabea HM. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection. Curr Med Sci 2021;41:581-6. [PMID: 34047942 DOI: 10.1007/s11596-021-2363-9] [Reference Citation Analysis]
189 Barré T, Ramier C, Di Beo V, Carrat F, Fontaine H, Marcellin F, Carrieri P, Pol S, Protopopescu C; ANRS/AFEF Hepather study group. Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER). Liver Int 2021;41:1694-8. [PMID: 33993651 DOI: 10.1111/liv.14949] [Reference Citation Analysis]
190 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
191 Parczewski M, Cielniak I, Kordek J, Aksak-wąs B, Urbańska A, Leszczyszyn-pynka M, Siwak E, Bociąga-jasik M, Nowak A, Szymczak A, Zalewska M, Łojewski W, Vandamme A, Lübke N, Cuypers L. Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland. JAIDS Journal of Acquired Immune Deficiency Syndromes 2018;77:514-22. [DOI: 10.1097/qai.0000000000001628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
192 Lee YB, Nam JY, Lee JH, Chang Y, Cho H, Cho YY, Cho EJ, Yu SJ, Kim HY, Lee DH, Lee JM, Hwang SG, Kim YJ, Yoon JH. Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Sci Rep 2018;8:13651. [PMID: 30209336 DOI: 10.1038/s41598-018-31839-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Andrade E, Rocha D, Fontana-Maurell M, Costa E, Ribeiro M, de Godoy DT, Ferreira AGP, Tanuri A, Alvarez P, Brindeiro R. One-step real-time PCR assay for detection and quantification of RNA HCV to monitor patients under treatment in Brazil. Braz J Infect Dis 2018;22:418-23. [PMID: 30243981 DOI: 10.1016/j.bjid.2018.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
194 Abid A, Uddin M, Muhammad T, Awan S, Applegate T, Dore GJ, Cloherty G, Hamid S. Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan. Diagnostics (Basel) 2021;11:1354. [PMID: 34441289 DOI: 10.3390/diagnostics11081354] [Reference Citation Analysis]
195 Sparkes T, Lemonovich TL; AST Infectious Diseases Community of Practice. Interactions between anti-infective agents and immunosuppressants-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13510. [PMID: 30817021 DOI: 10.1111/ctr.13510] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
196 Loggi E, Galli S, Vitale G, Di Donato R, Vukotic R, Grandini E, Margotti M, Guarneri V, Furlini G, Galli C, Re MC, Andreone P. Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods. PLoS One 2017;12:e0187755. [PMID: 29125869 DOI: 10.1371/journal.pone.0187755] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
197 Mücke MM, Mücke VT, Lange CM, Zeuzem S. Managing hepatitis C in patients with the complications of cirrhosis. Liver Int 2018;38 Suppl 1:14-20. [PMID: 29427491 DOI: 10.1111/liv.13636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
198 Merli M, Frigeni M, Alric L, Visco C, Besson C, Mannelli L, Di Rocco A, Ferrari A, Farina L, Pirisi M, Piazza F, Loustaud-Ratti V, Arcari A, Marino D, Sica A, Goldaniga M, Rusconi C, Gentile M, Cencini E, Benanti F, Rumi MG, Ferretti VV, Grossi P, Gotti M, Sciarra R, Tisi MC, Cano I, Zuccaro V, Passamonti F, Arcaini L. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. Oncologist. 2019;24:e720-e729. [PMID: 30552159 DOI: 10.1634/theoncologist.2018-0331] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
199 Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L, ANRS CO13 Hepavih study Group. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World J Hepatol 2018; 10(11): 856-866 [PMID: 30533186 DOI: 10.4254/wjh.v10.i11.856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
200 Yeon JE. Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. Clin Mol Hepatol 2018;24:278-93. [PMID: 29716179 DOI: 10.3350/cmh.2018.1002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
201 Onali S, Maida I, Balestrieri C, Arcadu F, Urru E, Porcu D, Serra G, Flore G, Dore E, Satta C, Paolo Bitti P, Grazia Sanna M, Serusi L, Casale M, Conti M, Loi M, Figorilli F, Cristina Pasetto M, Babudieri S, Chessa L. Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.61453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
202 Osawa M, Ueno T, Ishikawa H, Imai Y, Garimella T. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection. J Clin Pharmacol 2018;58:1468-78. [PMID: 30063254 DOI: 10.1002/jcph.1274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
203 Asselah T, Alami NN, Moreno C, Pol S, Karatapanis S, Gschwantler M, Horsmans Y, Elefsiniotis I, Larrey D, Ferrari C, Rizzetto M, Orlandini A, Calleja JL, Bruno S, Schnell G, Qaqish R, Redman R, Pilot-Matias T, Kopecky-Bromberg S, Yu Y, Mobashery N. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Sci Rep 2019;2:e92. [PMID: 30937389 DOI: 10.1002/hsr2.92] [Reference Citation Analysis]
204 Lei JH, Gong X, Xiao XQ, Chen Z, Peng F. Genotype distribution of hepatitis C virus in 952 cases from 2014 to 2016 in Hunan Province, China. Arch Med Sci 2018;14:1055-60. [PMID: 30154888 DOI: 10.5114/aoms.2017.70664] [Reference Citation Analysis]
205 Ueno T, Osawa M, Shiozaki T, Green M, Garimella T. Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients. Clin Pharmacol Drug Dev 2019;8:903-13. [PMID: 30667592 DOI: 10.1002/cpdd.646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Cordie A, Elsharkawy A, Abdel Alem S, Meshaal S, El Akel W, Abdellatif Z, Kamal W, Al Askalany M, Kamel S, Abdel Aziz H, Kandeel A, Esmat G. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. Trans R Soc Trop Med Hyg 2020;114:232-40. [PMID: 31925434 DOI: 10.1093/trstmh/trz120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
207 von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2018;47:1288-1295. [PMID: 29536554 DOI: 10.1111/apt.14592] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
208 Campello E, Radu CM, Zanetto A, Bulato C, Shalaby S, Spiezia L, Franceschet E, Burra P, Russo FP, Simioni P. Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int 2020;40:913-20. [PMID: 31454463 DOI: 10.1111/liv.14234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
209 Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, Schatz E, Tallada J, Harris M; Hep-CORE Study Group. Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. Int J Drug Policy 2017;47:47-50. [PMID: 28689856 DOI: 10.1016/j.drugpo.2017.05.054] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
210 Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
211 Emmanuel B, Wilson EM, O'Brien TR, Kottilil S, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol 2017;2:832-6. [PMID: 28802815 DOI: 10.1016/S2468-1253(17)30053-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
212 Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. J Hepatol 2018;68:814-26. [PMID: 29229584 DOI: 10.1016/j.jhep.2017.11.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
213 El Kassas M, Omran D, Elsaeed K, Alboraie M, Elakel W, El Tahan A, Abd El Latif Y, Nabeel MM, Korany M, Ezzat S. Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. J Interferon Cytokine Res. 2018;38:81-85. [PMID: 29356573 DOI: 10.1089/jir.2017.0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
214 Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy 2017;47:177-86. [DOI: 10.1016/j.drugpo.2017.05.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
215 Italian Association for the Study of the Liver (AISF). AISF position paper on HCV in immunocompromised patients. Dig Liver Dis 2019;51:10-23. [PMID: 30366813 DOI: 10.1016/j.dld.2018.09.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
216 He YL, Yang SJ, Hu CH, Dong J, Gao H, Yan TT, Liu JF, Yang Y, Ren DF, Zhu L, Zhao YR, Chen TY. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol Ther 2018;47:526-32. [DOI: 10.1111/apt.14429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
217 D'Ambrosio R, Aghemo A, Rumi MG, Degasperi E, Sangiovanni A, Maggioni M, Fraquelli M, Perbellini R, Rosenberg W, Bedossa P, Colombo M, Lampertico P. Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. Liver Int. 2018;38:1459-1467. [PMID: 29377616 DOI: 10.1111/liv.13707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
218 Molina-Cuadrado E, Mateo-Carrrasco H, Collado A, Casado Martín M. Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. Eur J Hosp Pharm 2018;25:132-7. [PMID: 31157007 DOI: 10.1136/ejhpharm-2017-001277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
219 Erice A, Varillas-Delgado D, Caballero C. Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain). J Viral Hepat 2021. [PMID: 34224188 DOI: 10.1111/jvh.13564] [Reference Citation Analysis]
220 Pascual-Argente N, Puig-Junoy J, Llagostera-Punzano A. Non-healthcare costs of hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 2018;12:19-30. [PMID: 28844170 DOI: 10.1080/17474124.2017.1373016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
221 Origa R, Ponti ML, Filosa A, Galeota Lanza A, Piga A, Saracco GM, Pinto V, Picciotto A, Rigano P, Madonia S, Rosso R, D'Ascola D, Cappellini MD, D'Ambrosio R, Tartaglione I, De Franceschi L, Gianesin B, Di Marco V, Forni GL; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol 2017;92:1349-55. [PMID: 28929515 DOI: 10.1002/ajh.24911] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
222 Perales C. Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance. Int J Antimicrob Agents 2020;56:105562. [PMID: 30315919 DOI: 10.1016/j.ijantimicag.2018.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
223 Elabd NS, Tayel SI, Elhamouly MS, Hassanein SA, Kamaleldeen SM, Ahmed FE, Rizk M, Gadallah AA, Ajlan SE, Sief AS. Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals. Hepat Med 2021;13:9-23. [PMID: 33758557 DOI: 10.2147/HMER.S292251] [Reference Citation Analysis]
224 Misra S, Dieterich DT, Saberi B, Kushner T. Direct-acting antiviral treatment of acute hepatitis C virus infections. Expert Rev Anti Infect Ther 2018;16:599-610. [PMID: 30067402 DOI: 10.1080/14787210.2018.1505502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
225 Rozera G, Fabbri G, Lorenzini P, Mastrorosa I, Timelli L, Zaccarelli M, Amendola A, Vergori A, Plazzi MM, Cicalini S, Antinori A, Capobianchi MR, Abbate I, Ammassari A. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. PLoS One 2017;12:e0187095. [PMID: 29077766 DOI: 10.1371/journal.pone.0187095] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
226 Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatol Int 2018;12:133-42. [PMID: 29600429 DOI: 10.1007/s12072-018-9859-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
227 Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025-2034. [PMID: 29703790 DOI: 10.1136/gutjnl-2018-316234] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 17.5] [Reference Citation Analysis]
228 Grassi A, Ballardini G. Hepatitis C in injection drug users: It is time to treat. World J Gastroenterol 2017; 23(20): 3569-3571 [PMID: 28611509 DOI: 10.3748/wjg.v23.i20.3569] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
229 Li C, Liang J, Xiang H, Chen H, Tian J. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine (Baltimore) 2020;99:e23384. [PMID: 33235113 DOI: 10.1097/MD.0000000000023384] [Reference Citation Analysis]
230 Gaeta GB, Puoti M, Coppola N, Santantonio T, Bruno R, Chirianni A, Galli M. Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases. Infection 2018;46:183-8. [PMID: 29238918 DOI: 10.1007/s15010-017-1107-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
231 Fedonin GG, Fantin YS, Favorov AV, Shipulin GA, Neverov AD. VirGenA: a reference-based assembler for variable viral genomes. Brief Bioinform 2019;20:15-25. [PMID: 28968771 DOI: 10.1093/bib/bbx079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
232 Libânio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol 2017; 23(26): 4669-4674 [PMID: 28765688 DOI: 10.3748/wjg.v23.i26.4669] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
233 Smith D, Magri A, Bonsall D, Ip CLC, Trebes A, Brown A, Piazza P, Bowden R, Nguyen D, Ansari MA, Simmonds P, Barnes E; STOP-HCV Consortium. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2019;69:1861-72. [PMID: 29425396 DOI: 10.1002/hep.29837] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
234 Crespo J, Lázaro de Mercado P, Blasco Bravo AJ, Aguilera Guirao A, García-samaniego Rey J, Eiros Bouza JM, Luis Calleja Panero J, García F. El diagnóstico de la infección por el virus de la hepatitis C en España: una oportunidad para mejorar. Enfermedades Infecciosas y Microbiología Clínica 2019;37:231-8. [DOI: 10.1016/j.eimc.2018.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
235 Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix M, Descamps D, Calvez V, Marcelin A. Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. Journal of Clinical Virology 2017;96:49-53. [DOI: 10.1016/j.jcv.2017.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
236 Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Med 2019;20:264-73. [PMID: 30734998 DOI: 10.1111/hiv.12711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
237 Han SY, Woo HY, Heo J, Park SG, Pyeon SI, Park YJ, Kim DU, Kim GH, Kim HH, Song GA, Cho M. The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2. Korean J Intern Med 2021;36:544-56. [PMID: 30879288 DOI: 10.3904/kjim.2018.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
238 van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky J, Cloherty GA, Duarte-rojo A, Sarrazin C, Wedemeyer H, Feld JJ. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. The Lancet Gastroenterology & Hepatology 2018;3:856-64. [DOI: 10.1016/s2468-1253(18)30271-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
239 Behairy BE, El-Araby HA, El-Guindi MA, Basiouny HM, Fouad OA, Ayoub BA, Marei AM, Sira MM. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. J Pediatr 2020;219:106-10. [PMID: 32008767 DOI: 10.1016/j.jpeds.2019.12.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
240 Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 2019;54:1042-50. [PMID: 31424972 DOI: 10.1080/00365521.2019.1652846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
241 Martinello M, Dore GJ, Matthews GV, Grebely J. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infect Dis Clin North Am 2018;32:371-93. [PMID: 29778261 DOI: 10.1016/j.idc.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
242 Ward Z, Platt L, Sweeney S, Hope VD, Maher L, Hutchinson S, Palmateer N, Smith J, Craine N, Taylor A, Martin N, Ayres R, Dillon J, Hickman M, Vickerman P. Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? Addiction 2018. [PMID: 29774607 DOI: 10.1111/add.14217] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
243 Łucejko M, Flisiak R. Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C. Applied Sciences 2018;8:198. [DOI: 10.3390/app8020198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
244 Mari PC, Gulati R, Fragassi P. Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. Adolesc Health Med Ther 2021;12:45-53. [PMID: 33994820 DOI: 10.2147/AHMT.S263864] [Reference Citation Analysis]
245 Invernizzi F, Aghemo A. Treatment of chronic hepatitis C: can complexity pave the way towards elimination? Lancet Gastroenterol Hepatol 2017;2:465-6. [PMID: 28416220 DOI: 10.1016/S2468-1253(17)30085-7] [Reference Citation Analysis]
246 Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, Wang H, Guo X, Zhou H, Tao W, Xie Q. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Front Microbiol 2019;10:535. [PMID: 30941111 DOI: 10.3389/fmicb.2019.00535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
247 Mulabecirovic A, Mjelle AB, Gilja OH, Vesterhus M, Havre RF. Repeatability of shear wave elastography in liver fibrosis phantoms-Evaluation of five different systems. PLoS One 2018;13:e0189671. [PMID: 29293527 DOI: 10.1371/journal.pone.0189671] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
248 Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, Subirana M, Moreno A, Aguilera V, Luisa González-Diéguez M, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Manuel Sousa J, Suarez F, Serrano T, Ignacio Herrero J, Jiménez M, Fernandez JR, Giménez C, Del Campo S, Esteban-Mur JI, Crespo G, Moreno A, de la Rosa G, Rimola A, Miro JM; FIPSE LT-HIV investigators. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. Am J Transplant 2018;18:2513-22. [PMID: 29963780 DOI: 10.1111/ajt.14996] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
249 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol 2017;23:4317-23. [PMID: 28706414 DOI: 10.3748/wjg.v23.i24.4317] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
250 Berenguer J, Gil-Martin Á, Jarrin I, Moreno A, Dominguez L, Montes M, Aldámiz-Echevarría T, Téllez MJ, Santos I, Benitez L, Sanz J, Ryan P, Gaspar G, Alvarez B, Losa JE, Torres-Perea R, Barros C, Martin JVS, Arponen S, de Guzmán MT, Monsalvo R, Vegas A, Garcia-Benayas MT, Serrano R, Gotuzzo L, Menendez MA, Belda LM, Malmierca E, Calvo MJ, Cruz-Martos E, González-García JJ. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology 2018;68:32-47. [PMID: 29377274 DOI: 10.1002/hep.29814] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
251 Ponnuvel S, Fletcher GJ, Anantharam R, Varughese S, David VG, Abraham P. Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients. PLoS One 2021;16:e0250263. [PMID: 33886631 DOI: 10.1371/journal.pone.0250263] [Reference Citation Analysis]
252 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
253 Lee JS, Choi HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. J Gastroenterol Hepatol 2021. [PMID: 33788314 DOI: 10.1111/jgh.15514] [Reference Citation Analysis]
254 Johnson SW, Teachey AL, Valanejad SM, Griffin SM, Weber SF. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass. J Clin Pharm Ther 2017;42:624-6. [PMID: 28474386 DOI: 10.1111/jcpt.12547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
255 Johnson SW, Ammirati SR, Hartis CE, Weber SF, Morgan MR, Darnell TA, Silwal A, Schmidlin HN, Priest DH. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach. Int J Antimicrob Agents 2017;49:778-81. [PMID: 28389353 DOI: 10.1016/j.ijantimicag.2017.01.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
256 Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Rev Inst Med Trop Sao Paulo 2017;59:e67. [PMID: 29116287 DOI: 10.1590/S1678-9946201759067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
257 Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8. [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6] [Cited by in Crossref: 217] [Cited by in F6Publishing: 87] [Article Influence: 43.4] [Reference Citation Analysis]
258 D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, Messina E, Fanetti I, Puoti M, Aghemo A, Viganò P, Vinci M, Menzaghi B, Lombardi A, Pan A, Pigozzi MG, Grossi P, Lazzaroni S, Spinelli O, Invernizzi P, Maggiolo F, Terreni N, Monforte AD, Poggio PD, Taddei MT, Colombo S, Pozzoni P, Molteni C, Brocchieri A, Bhoori S, Buscarini E, Centenaro R, Mendeni M, Colombo AE, Di Marco M, Dionigi E, Bella D, Borghi M, Zuin M, Zaltron S, Noventa F, Annalisa S, Lampertico P, Fagiuoli S. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Dig Liver Dis 2020;52:190-8. [PMID: 31813755 DOI: 10.1016/j.dld.2019.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
259 Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry. HIV Clin Trials 2018;19:225-34. [PMID: 30890063 DOI: 10.1080/15284336.2018.1538193] [Reference Citation Analysis]
260 Wiesmann F, Naeth G, Berger A, Hirsch HH, Regenass S, Ross RS, Sarrazin C, Wedemeyer H, Knechten H, Braun P. Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment. Med Microbiol Immunol 2016;205:263-8. [PMID: 26666643 DOI: 10.1007/s00430-015-0443-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
261 Rhodes T, Lancaster K. Excitable models: Projections, targets, and the making of futures without disease. Sociol Health Illn 2021;43:859-80. [PMID: 33942914 DOI: 10.1111/1467-9566.13263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
263 Carnovale C, Pozzi M, Dassano A, D'Addio F, Gentili M, Magni C, Clementi E, Radice S, Fiorina P. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetol. 2019;56:341-354. [PMID: 30478781 DOI: 10.1007/s00592-018-1257-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
264 Hollande C, Parlati L, Pol S. Micro-elimination of hepatitis C virus. Liver Int. 2020;40 Suppl 1:67-71. [PMID: 32077601 DOI: 10.1111/liv.14363] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
265 Hu C, Yuan G, Liu J, Huang H, Ren Y, Li Y, Chen X, Li W, Wu T, Deng H, Peng Y, Zhang YY, Zhou Y. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. Can J Gastroenterol Hepatol 2018;2018:3908767. [PMID: 30538973 DOI: 10.1155/2018/3908767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
266 Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
267 Persico M, Masarone M, Aglitti A, Armenante C, Giordano A, Guardiola A, Raimondi G, Contaldi C, Nigro C, Marena G, De Luna A. HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy. Liver Int. 2019;39:1845-1851. [PMID: 31169953 DOI: 10.1111/liv.14166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
268 Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, Aichelburg MC, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United European Gastroenterol J 2019;7:507-16. [PMID: 31065368 DOI: 10.1177/2050640619835394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
269 Zamani F, Ajdarkosh H, Safarnezhad-Tameshkel F, Azarkeivan A, Keyvani H, Naserifar F, Vafaeimanesh J. The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors. Indian J Med Microbiol 2018;36:224-9. [PMID: 30084415 DOI: 10.4103/ijmm.IJMM_18_90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
270 Gane EJ, DeJesus E, Janczewska E, George J, Diago M, Da Silva MH, Reesink H, Nikitin I, Hinrichsen H, Bourgeois S, Ferenci P, Shukla U, Kalmeijer R, Lenz O, Fevery B, Corbett C, Beumont M, Jessner W. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. BMC Infect Dis 2017;17:389. [PMID: 28577353 DOI: 10.1186/s12879-017-2444-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
271 Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'rear JJ, Naeger LK. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 2018;67:2430-48. [DOI: 10.1002/hep.29693] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
272 Tian T, Wang J, Huang P, Li J, Yu R, Fan H, Xia X, Han Y, Zhang Y, Yue M. Genetic variations in NF-κB were associated with the susceptibility to hepatitis C virus infection among Chinese high-risk population. Sci Rep 2018;8:104. [PMID: 29311624 DOI: 10.1038/s41598-017-18463-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
273 Ko SY, Choe WH. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clin Mol Hepatol 2018;24:351-7. [PMID: 29544240 DOI: 10.3350/cmh.2017.0063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
274 Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C. Clin Exp Hepatol 2017;3:198-202. [PMID: 29255808 DOI: 10.5114/ceh.2017.71337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
275 Wu DB, Jiang W, Wang YH, Chen B, Wang ML, Tao YC, Chen EQ, Tang H. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. J Viral Hepat 2019;26:316-22. [PMID: 30380166 DOI: 10.1111/jvh.13033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
276 Knops E, Sierra S, Kalaghatgi P, Heger E, Kaiser R, Kalinina OV. Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms. Genes (Basel) 2018;9:E343. [PMID: 29986475 DOI: 10.3390/genes9070343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
277 Morey S, Hamoodi A, Jones D, Young T, Thompson C, Dhuny J, Buchanan E, Miller C, Hewett M, Valappil M, Hunter E, McPherson S. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. J Viral Hepat. 2019;26:101-108. [PMID: 30315691 DOI: 10.1111/jvh.13017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
278 Gomes LO, Teixeira MR, Rosa JAD, Foppa AA, Rover MRM, Farias MR. The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy. Res Social Adm Pharm 2020;16:48-53. [PMID: 30853508 DOI: 10.1016/j.sapharm.2019.02.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
279 Morales-Arraez D, Hernandez-Guerra M, Diaz-Flores F, Nieto-Bujalance Y, Garcia-Dopico J, Jimenez A, Quintero E. Hepatitis C virus media coverage favorably impacts on antibody testing in the non-interferon era. J Public Health (Oxf) 2021;43:385-91. [PMID: 31786606 DOI: 10.1093/pubmed/fdz149] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K; Polish Group of Experts for HCV. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol 2017;3:47-55. [PMID: 28856290 DOI: 10.5114/ceh.2017.67782] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
281 Kawakami Y, Ochi H, Hayes CN, Imamura M, Tsuge M, Nakahara T, Katamura Y, Kohno H, Kohno H, Tsuji K. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. J Gastroenterol. 2018;53:548-556. [PMID: 28815329 DOI: 10.1007/s00535-017-1380-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
282 Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc 2018;21 Suppl 2:e25058. [PMID: 29633561 DOI: 10.1002/jia2.25058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
283 Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo Saez M; GRUviC Study Group. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. Expert Opin Drug Saf 2018;17:235-41. [PMID: 29325476 DOI: 10.1080/14740338.2018.1424829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
284 Arora A, Singh SP, Kumar A, Saraswat VA, Aggarwal R, Bangar M, Bhaumik P, Devarbhavi H, Dhiman RK, Dixit VK, Goel A, Goswami B, Kapoor D, Madan K, Narayan J, Nijhawan S, Pandey G, Rai RR, Sahu MK, Saraf N, Shalimar, Shenoy T, Thomas V, Wadhawan M; INASL Hepatitis B Taskforce. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. J Clin Exp Hepatol 2018;8:58-80. [PMID: 29743798 DOI: 10.1016/j.jceh.2017.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
285 Singer JB, Thomson EC, McLauchlan J, Hughes J, Gifford RJ. GLUE: a flexible software system for virus sequence data. BMC Bioinformatics 2018;19:532. [PMID: 30563445 DOI: 10.1186/s12859-018-2459-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
286 Rezaee-zavareh MS, Hesamizadeh K, Sharafi H, Alavian SM. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
287 Childs K, Merritt E, Considine A, Sanchez-Fueyo A, Agarwal K, Martinez-Llordella M, Carey I. Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis. Open Forum Infect Dis. 2017;4:ofx067. [PMID: 28584852 DOI: 10.1093/ofid/ofx067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
288 Catlett B, Lamoury FMJ, Bajis S, Hajarizadeh B, Martinez D, Mowat Y, Cunningham PH, Jacka BP, Cloherty GA, Marks P, Dore GJ, Grebely J, Applegate TL. Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. J Viral Hepat 2019;26:1423-30. [PMID: 31448470 DOI: 10.1111/jvh.13196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
289 Raja R, Pareek A, Newar K, Dixit NM. Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs. PLoS Pathog 2019;15:e1007701. [PMID: 30934020 DOI: 10.1371/journal.ppat.1007701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
290 Aghemo A, Piroth L, Bhagani S. What do clinicians need to watch for with direct-acting antiviral therapy? J Int AIDS Soc 2018;21 Suppl 2:e25076. [PMID: 29633552 DOI: 10.1002/jia2.25076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
291 Fernández-Caballero JA, Alvarez M, Chueca N, Pérez AB, García F. The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. PLoS One 2017;12:e0175564. [PMID: 28410425 DOI: 10.1371/journal.pone.0175564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
292 Höner Zu Siederdissen C, Schlevogt B, Solbach P, Port K, Cornberg M, Manns MP, Wedemeyer H, Deterding K. Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. Liver Int 2018;38:834-41. [PMID: 28960793 DOI: 10.1111/liv.13601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
293 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. Diagnostics (Basel). 2020;10. [PMID: 33276638 DOI: 10.3390/diagnostics10121037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med 2018;19:299-307. [PMID: 29368456 DOI: 10.1111/hiv.12579] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
295 Bartenschlager R, Cornberg M, Pietschmann T. [Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E]. Internist (Berl) 2017;58:666-74. [PMID: 28631044 DOI: 10.1007/s00108-017-0262-8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
296 Abdel Alem S, Elsharkawy A, El Akel W, Abdelaziz AO, Salama RM, El-Sayed MH, El Kassas M, Anees M, Shedeed M, Abdelsalam F, Ziada DH, El Shazly Y, El-Serafy M, Waked I, Esmat G, Doss W. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Rev Gastroenterol Hepatol 2019;13:1009-16. [PMID: 31418303 DOI: 10.1080/17474124.2019.1653183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
297 Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, Alvarez J, Pulido L, Cañamares I, Escobar I, Moreno S, Ryan P. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy 2019;72:181-8. [PMID: 31253391 DOI: 10.1016/j.drugpo.2019.06.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
298 Rockstroh JK. [HCV healing also in HIV infected patients]. MMW Fortschr Med 2017;159:56-60. [PMID: 28597261 DOI: 10.1007/s15006-017-9739-6] [Reference Citation Analysis]
299 Mohamed AA, El-Toukhy NER, Said EM, Gabal HMR, AbdelAziz H, Doss W, El-Hanafi H, El Deeb HH, Mahmoud S, Elkadeem M, Shalby HS, Abd-Elsalam S. Hepatitis C Virus: Efficacy of New DAAs Regimens. Infect Disord Drug Targets 2020;20:143-9. [PMID: 30663575 DOI: 10.2174/1871526519666190121114003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
300 Llibre A, Shimakawa Y, Mottez E, Ainsworth S, Buivan TP, Firth R, Harrison E, Rosenberg AR, Meritet JF, Fontanet A, Castan P, Madejón A, Laverick M, Glass A, Viana R, Pol S, McClure CP, Irving WL, Miele G, Albert ML, Duffy D. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut 2018;67:2017-24. [PMID: 29615488 DOI: 10.1136/gutjnl-2017-315783] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
301 Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group. Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany? J Clin Gastroenterol 2020;54:192-9. [PMID: 30789853 DOI: 10.1097/MCG.0000000000001189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
302 Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C. Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. J Infect Chemother. 2018;24:524-530. [PMID: 29628383 DOI: 10.1016/j.jiac.2018.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
303 Hoornenborg E, Achterbergh RC, Schim van der Loeff MF, Davidovich U, Hogewoning A, de Vries HJ, Schinkel J, Prins M, van de Laar TJ. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS 2017;31:1603-10. [DOI: 10.1097/qad.0000000000001522] [Cited by in Crossref: 89] [Cited by in F6Publishing: 37] [Article Influence: 17.8] [Reference Citation Analysis]
304 van Boemmel-Wegmann S, Lo Re V 3rd, Park H. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Dig Dis Sci 2020;65:3159-74. [PMID: 31938995 DOI: 10.1007/s10620-019-06037-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Zeng QL, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, Liang HX, Li CX, Yu ZJ. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. J Hepatol 2017;66:1123-9. [PMID: 28189754 DOI: 10.1016/j.jhep.2017.01.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
306 Crespo J, Lázaro P, Blasco AJ, Aguilera A, García-Samaniego J, Eiros JM, Calleja JL, García F. Hepatitis C reflex testing in Spain in 2019: A story of success. Enferm Infecc Microbiol Clin (Engl Ed) 2021;39:119-26. [PMID: 32451150 DOI: 10.1016/j.eimc.2020.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
307 Di Minno MND, Ambrosino P, Buonomo AR, Pinchera B, Calcaterra I, Crispo M, Scotto R, Borgia F, Mattia C, Gentile I. Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. Intern Emerg Med 2020;15:263-71. [PMID: 31396919 DOI: 10.1007/s11739-019-02163-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
308 Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417-426. [PMID: 28951228 DOI: 10.1016/j.cgh.2017.09.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 128] [Article Influence: 28.6] [Reference Citation Analysis]
309 Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. J Gastrointest Cancer 2020;51:584-90. [PMID: 31407252 DOI: 10.1007/s12029-019-00293-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
310 Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453-1464. [PMID: 30765123 DOI: 10.1016/s0140-6736(18)32111-1] [Cited by in Crossref: 207] [Cited by in F6Publishing: 77] [Article Influence: 69.0] [Reference Citation Analysis]
311 Dammacco F, Lauletta G, Russi S, Leone P, Tucci M, Manno C, Monaco S, Ferrari S, Vacca A, Racanelli V. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med. 2019;19:1-21. [PMID: 30430284 DOI: 10.1007/s10238-018-0536-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
312 Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018;12:331-9. [DOI: 10.1080/17474124.2018.1439379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
313 Guaraldi G, Rossotti R, Verucchi G, Tavio M, Pasulo L, Beghetto B, Dolci G, Nardini G, Badia L, Magliano A, Moioli MC, Puoti M; HIV/HCV Italian Liver Transplant Group . Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection. Open Forum Infect Dis 2017;4:ofx065. [PMID: 28584851 DOI: 10.1093/ofid/ofx065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
314 Foschi FG, Borghi A, Grassi A, Lanzi A, Speranza E, Vignoli T, Napoli L, Olivoni D, Sanza M, Polidori E, Greco G, Bassi P, Cristini F, Ballardini G, Altini M, Conti F, On Behalf Of Mith Group. Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs. J Clin Med 2021;10:4001. [PMID: 34501448 DOI: 10.3390/jcm10174001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Zubkin ML, Shchepetkova GS, Balkarova OV, Chervinko VI, Kryukov EV. Successful Hepatitis C Virus Eradication in a Hemodialysis Patient With 2k/1b Chimera Genotype: A Case Report and Literature Review. Gastroenterology Res 2019;12:176-80. [PMID: 31236161 DOI: 10.14740/gr1171] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
316 Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infect Dis 2018;5:ofy248. [PMID: 30430131 DOI: 10.1093/ofid/ofy248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
317 Pol S, Vallet-Pichard A, Hermine O. Extrahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2018;15:283-290. [PMID: 29339810 DOI: 10.1038/nrgastro.2017.172] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
318 Antón MD, Polanco A, Ferrando I, Latorre P, Pascual A, Moreno Osset E. Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals. Gastroenterol Hepatol 2018;41:317-9. [PMID: 28728831 DOI: 10.1016/j.gastrohep.2017.06.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
319 Palladino C, Sánchez-Carrillo M, Mate-Cano I, Vázquez-Morón S, Jimenez-Sousa MÁ, Gutiérrez-Rivas M, Resino S, Briz V. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Sci Rep 2017;7:2892. [PMID: 28588311 DOI: 10.1038/s41598-017-02968-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
320 Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 2018;5:ofy120. [PMID: 29992173 DOI: 10.1093/ofid/ofy120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
321 Pellicelli A, Giannelli V, Zoli V, Pellicelli V, Zignego AL. Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. Clin Exp Hepatol. 2018;4:197-200. [PMID: 30324145 DOI: 10.5114/ceh.2018.78124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
322 Garioud A, Heng R, Amiot X, Rémy AJ, Ollivier-Hourmand I, Mokhtari C, Medmoun M, Renou C, Zougmoré H, Pulwermacher P, Lucidarme D, Rosa-Hézode I, Causse X, Arotcarena R, Zanditenas D, Halfon P, Pariente A, Cadranel JF; Association Nationale des Hépato-gastroentérologues des Hôpitaux Généraux (ANGH), France. Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients. Eur J Gastroenterol Hepatol 2019;31:1270-4. [PMID: 31219848 DOI: 10.1097/MEG.0000000000001450] [Reference Citation Analysis]
323 Larrey D, Meunier L, Ursic-Bedoya J. Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance? Ann Hepatol. 2017;16:487-489. [PMID: 28612749 DOI: 10.5604/01.3001.0010.0272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
324 Torrecillas M, Gómez-Muñoz N, Ocete MD, Cuevas PR, Madrid MD, González EO, Cardona CG, García-Deltoro M. One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection. Ann Hepatol 2021;27:100542. [PMID: 34571265 DOI: 10.1016/j.aohep.2021.100542] [Reference Citation Analysis]
325 Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB, Song MJ, Jang JW, Ko SY, Lee JD. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Clin Mol Hepatol 2018;24:311-8. [PMID: 29865774 DOI: 10.3350/cmh.2017.0070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
326 Yousif MM, Ahmed H, Elsadek HM, Shendi AM, Gouda TM, Elsayed IA, Gendia MA, Magdy MM, Lbrahim NF, Sadek AMEM, Zaki AM, Shafeik H, Zahran MH. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies. J Viral Hepat 2020;27:1190-201. [PMID: 32564500 DOI: 10.1111/jvh.13349] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Chen P, Yang H, Chou C, Chang L, Hsu M, Tsai T, Fang C, Su C, Lin Y, Feng Y, Chen C. The effectiveness and safety of sofosbuvir‐ledipasvir for patients with hepatitis C virus genotype 2 infection. Adv in Digestive Med. [DOI: 10.1002/aid2.13258] [Reference Citation Analysis]
328 Parlati L, Laurain A, Pol S. Epidemiology update for HCV and HBV in ESRD in France: Still a lot to do. Liver Int 2017;37:815-6. [PMID: 28544694 DOI: 10.1111/liv.13414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 Chamorro-de-Vega E, Rodriguez-Gonzalez CG, Gimenez-Manzorro A, de Lorenzo-Pinto A, Iglesias-Peinado I, Herranz A, Sanjurjo M; GRUviC Study Group. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project. Int J Clin Pract 2017;71. [PMID: 28836363 DOI: 10.1111/ijcp.12988] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
330 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Reference Citation Analysis]
331 Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. J Viral Hepat 2021;28:558-68. [PMID: 33306247 DOI: 10.1111/jvh.13454] [Reference Citation Analysis]
332 Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis 2018;18:223. [PMID: 29769038 DOI: 10.1186/s12879-018-3125-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
333 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
334 Persico M, Aglitti A, Caruso R, De Renzo A, Selleri C, Califano C, Abenavoli L, Federico A, Masarone M. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. Hepatology. 2018;67:48-55. [PMID: 28714143 DOI: 10.1002/hep.29364] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
335 Imperatore N, Castiglione F, Rispo A, Sessa A, Caporaso N, Morisco F. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Front Pharmacol 2017;8:867. [PMID: 29209223 DOI: 10.3389/fphar.2017.00867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
336 Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol 2018;68:597-600. [PMID: 28939133 DOI: 10.1016/j.jhep.2017.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
337 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
338 Fernandes FF, Perazzo H, Andrade LE, Dellavance A, Terra C, Pereira G, Pereira JL, Campos F, Ferraz ML, Perez RM. Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard. Biomed Res Int 2017;2017:8252980. [PMID: 29057268 DOI: 10.1155/2017/8252980] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
339 Doncheva NT, Domingues FS, McGivern DR, Shimakami T, Zeuzem S, Lengauer T, Lange CM, Albrecht M, Welsch C. Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants. J Mol Biol 2019;431:2354-68. [PMID: 31051172 DOI: 10.1016/j.jmb.2019.04.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
340 Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N. Virological patterns of HCV patients with failure to interferon-free regimens. J Med Virol. 2018;90:942-950. [PMID: 29315640 DOI: 10.1002/jmv.25022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
341 Soriano V, Labarga P, Fernandez-montero JV, Mendoza CD, Benítez-gutiérrez L, Peña JM, Barreiro P. Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 2017;13:807-16. [DOI: 10.1080/17425255.2017.1351942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
342 Mazzarelli C, Cannon MD, Belli LS, Agarwal K. Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything. Journal of Hepatology 2018;68:217-8. [DOI: 10.1016/j.jhep.2017.08.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
343 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
344 Broquetas T, Herruzo-Pino P, Mariño Z, Naranjo D, Vergara M, Morillas RM, Forns X, Carrión JA. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. Liver Int 2021;41:2733-46. [PMID: 34525253 DOI: 10.1111/liv.15058] [Reference Citation Analysis]
345 Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-matias T, Lu W, Cohen DE, Feld JJ. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. The Lancet Gastroenterology & Hepatology 2017;2:494-500. [DOI: 10.1016/s2468-1253(17)30071-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
346 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
347 McDonald SA, Innes HA, Aspinall EJ, Hayes PC, Alavi M, Valerio H, Goldberg DJ, Hutchinson SJ. Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis. Liver Int. 2018;38:1402-1410. [PMID: 29288595 DOI: 10.1111/liv.13681] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
348 Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology 2021;73:1275-89. [PMID: 32659847 DOI: 10.1002/hep.31462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
349 Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee CH, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Lee JH, Kim SU. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2020;32:378-385. [PMID: 32011388 DOI: 10.1097/meg.0000000000001512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
350 Walker JG, Mafirakureva N, Iwamoto M, Campbell L, Kim CS, Hastings RA, Doussett JP, Le Paih M, Balkan S, Marquardt T, Maman D, Loarec A, Coast J, Vickerman P. Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia. Liver Int 2020;40:2356-66. [PMID: 32475010 DOI: 10.1111/liv.14550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
351 Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londoño MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2017;2:585-94. [PMID: 28576451 DOI: 10.1016/S2468-1253(17)30116-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 15] [Article Influence: 10.8] [Reference Citation Analysis]
352 Berenguer J. Eliminación del virus de la hepatitis C en España: un reto pendiente. Enfermedades Infecciosas y Microbiología Clínica 2018;36:323-4. [DOI: 10.1016/j.eimc.2018.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
353 Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment. Clin Exp Hepatol 2017;3:187-93. [PMID: 29255806 DOI: 10.5114/ceh.2017.71079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
354 Cacoub P. Comment on Nuño Solinís R, et al. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence". Infect Dis Ther 2017;6:297-301. [PMID: 28357707 DOI: 10.1007/s40121-017-0155-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
355 Haider L, Mandorfer M, Güngören Z, Reiberger T, Bastati N, Hodge JC, Chromy D, Trauner M, Herold C, Peck-Radosavljevic M, Ba-Ssalamah A. Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI. Contrast Media Mol Imaging 2018;2018:8489709. [PMID: 30116164 DOI: 10.1155/2018/8489709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
356 Marascio N, Pavia G, Romeo I, Talarico C, Di Salvo S, Reale M, Marano V, Barreca GS, Fabiani F, Perrotti N, De Siena M, Giancotti F, Gravina T, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling. J Med Virol 2018;90:1257-63. [PMID: 29575060 DOI: 10.1002/jmv.25073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
357 Indolfi G, Serranti D, Resti M. Direct-acting antivirals for children and adolescents with chronic hepatitis C. The Lancet Child & Adolescent Health 2018;2:298-304. [DOI: 10.1016/s2352-4642(18)30037-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 4.3] [Reference Citation Analysis]
358 Yukawa Y, Tamori A, Iio E, Ogawa S, Yoshida K, Uchida-Kobayashi S, Enomoto M, Tanaka Y, Kawada N. Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse? Clin J Gastroenterol 2019;12:598-602. [PMID: 31165460 DOI: 10.1007/s12328-019-01001-w] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
359 Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol 2018; 24(11): 1269-1277 [PMID: 29568207 DOI: 10.3748/wjg.v24.i11.1269] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
360 Vivancos M, Moreno A, Quereda C. Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual. Revista Clínica Española 2018;218:29-37. [DOI: 10.1016/j.rce.2017.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
361 Boschi C, Colson P, Tissot-Dupont H, Bernit E, Botta-Fridlund D, Aherfi S. Hepatitis C Virus Relapse 78 Weeks After Completion of Successful Direct-Acting Therapy. Clin Infect Dis 2017;65:1051-3. [PMID: 28510632 DOI: 10.1093/cid/cix457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
362 Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, Serio I, Verrucchi G, Bacchi Reggiani ML, Colli A, Marasco G, Colecchia A, Festi D. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis. 2018;50:573-579. [PMID: 29567413 DOI: 10.1016/j.dld.2018.02.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
363 Ippolito G, Zumla A, Lanini S. Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C? Clin Microbiol Infect 2018;24:328-31. [PMID: 29326009 DOI: 10.1016/j.cmi.2018.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
364 Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12216] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
365 Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther 2017;46:424-31. [PMID: 28660640 DOI: 10.1111/apt.14197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
366 Ridruejo E, Mendizabal M, Silva MO. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease: HCV in CKD stages 2-3. Hemodialysis International 2018;22:S97-S103. [DOI: 10.1111/hdi.12651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
367 Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. J Hepatol 2017;66:711-7. [PMID: 27965158 DOI: 10.1016/j.jhep.2016.12.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
368 Lens S, Fernández I, Rodríguez-Tajes S, Hontangas V, Vergara M, Forné M, Calleja JL, Diago M, Llaneras J, Llerena S, Torras X, Sacristán B, Roget M, Fernández-Rodríguez CM, Navascués MC, Fuentes J, Sánchez-Ruano JJ, Simón MÁ, Sáez-Royuela F, Baliellas C, Morillas R, Forns X; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. Am J Gastroenterol 2017;112:1400-9. [PMID: 28585554 DOI: 10.1038/ajg.2017.157] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
369 Haridy J, Wigg A, Muller K, Ramachandran J, Tilley E, Waddell V, Gordon D, Shaw D, Huynh D, Stewart J, Nelson R, Warner M, Boyd M, Chinnaratha MA, Harding D, Ralton L, Colman A, Liew D, Iyngkaran G, Tse E; the Adelaide Liver Group. Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience. J Viral Hepat 2018;25:1287-97. [DOI: 10.1111/jvh.12943] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
370 Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterol J 2018;6:213-24. [PMID: 29511551 DOI: 10.1177/2050640617716607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
371 Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 2018;18:446. [PMID: 30176817 DOI: 10.1186/s12879-018-3356-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
372 Russo FP, Zanetto A, Gambato M, Bortoluzzi I, Al Zoairy R, Franceschet E, De Marchi F, Marzi L, Lynch EN, Floreani A, Farinati F, Schaefer B, Burra P, Zoller H, Mega A. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J Viral Hepat 2020;27:188-94. [PMID: 31596996 DOI: 10.1111/jvh.13215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
373 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the treatment of patients with genotype 3a infection and compensated cirrhosis. J Hepatol 2019;70:562-4. [PMID: 30439391 DOI: 10.1016/j.jhep.2018.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
374 Yang X, Ding T, Huang H, Xu Y, Yu J, Chen Z. Development and validation of a simple and rapid method for hepatitis C virus genotyping based on one-step RT-qPCR. Exp Ther Med 2020;20:2284-90. [PMID: 32765706 DOI: 10.3892/etm.2020.8912] [Reference Citation Analysis]
375 van Tilborg M, Maan R, van der Meer AJ, de Knegt RJ. Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. Best Pract Res Clin Gastroenterol 2017;31:219-25. [PMID: 28624110 DOI: 10.1016/j.bpg.2017.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
376 McHugh MP, Wu AHB, Chevaliez S, Pawlotsky JM, Hallin M, Templeton KE. Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. J Clin Microbiol 2017;55:1550-6. [PMID: 28275079 DOI: 10.1128/JCM.02460-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 6.6] [Reference Citation Analysis]
377 Visco-Comandini U, Lapa D, Lionetti R, Taibi C, Loiacono L, Montalbano M, Capobianchi MR, D'Offizi G, Garbuglia AR. Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols. J Med Virol 2018;90:1264-71. [PMID: 29611880 DOI: 10.1002/jmv.25084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
378 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
379 Karkampouna S, van der Helm D, Scarpa M, van Hoek B, Verspaget HW, Goumans MJ, Coenraad MJ, Kruithof BPT, Kruithof-de Julio M. Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis. Cells 2021;10:3325. [PMID: 34943832 DOI: 10.3390/cells10123325] [Reference Citation Analysis]
380 Garssen J, Jo J; 1 Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands, 2 Department of Immunology, Nutricia Research, Utrecht, the Netherlands, 3 Department of Immunology, Nutricia Research, Singapore. . AIMS Allergy and Immunology 2017;1:43-9. [DOI: 10.3934/allergy.2017.1.43] [Reference Citation Analysis]
381 Papatheodoridi Μ, Dalekos GN, Goulis J, Manolakopoulos S, Triantos C, Zachou K, Koukoufiki A, Κourikou Α, Ζisimopoulos Κ, Τsoulas C, Papatheodoridis GV. Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. Ann Gastroenterol 2017;30:542-9. [PMID: 28845110 DOI: 10.20524/aog.2017.0170] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
382 He Y, Wang Y, Chen X, Huang H, Deng J, Chen P, Bin H. Performance evaluation of the DAAN HCV assay for quantification of hepatitis C virus RNA and its comparison with COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0. J Clin Lab Anal 2020;34:e23280. [PMID: 32167624 DOI: 10.1002/jcla.23280] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
383 Reig M, Boix L, Bruix J. The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver Int 2017;37 Suppl 1:136-9. [PMID: 28052619 DOI: 10.1111/liv.13321] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
384 Calvaruso V, Petta S, Craxì A. Is global elimination of HCV realistic? Liver Int 2018;38 Suppl 1:40-6. [PMID: 29427499 DOI: 10.1111/liv.13668] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
385 Shahid I, Alzahrani AR, Al-Ghamdi SS, Alanazi IM, Rehman S, Hassan S. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics (Basel) 2021;11:1253. [PMID: 34359335 DOI: 10.3390/diagnostics11071253] [Reference Citation Analysis]
386 Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Torres HA, Bailey HH. Oncologic Implications of Chronic Hepatitis C Virus Infection. J Oncol Pract 2019;15:629-37. [PMID: 31825756 DOI: 10.1200/JOP.19.00370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
387 Chromy D, Schwabl P, Bucsics T, Scheiner B, Strassl R, Mayer F, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients. Wien Klin Wochenschr 2018;130:105-14. [PMID: 28744597 DOI: 10.1007/s00508-017-1231-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
388 Örmeci N, Sezgin O, Karaali R, Aygen B, Turan D, Yaras S, Erdem İ, Yildiz O, Karakaya F, Ateş K, Asiller ÖÖ. Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences. Eur J Gastroenterol Hepatol 2019;31:534-9. [PMID: 30672829 DOI: 10.1097/MEG.0000000000001334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
389 El Missiri AM, Rayan MM, Awad MM, El Desoky AI. Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring. Egypt Heart J 2020;72:37. [PMID: 32613565 DOI: 10.1186/s43044-020-00070-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
390 Ruiz I, Nevers Q, Hernández E, Ahnou N, Brillet R, Softic L, Donati F, Berry F, Hamadat S, Fourati S, Pawlotsky JM, Ahmed-Belkacem A. MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication. Antimicrob Agents Chemother 2020;64:e02078-19. [PMID: 32179525 DOI: 10.1128/AAC.02078-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15:412-424. [PMID: 29773899 DOI: 10.1038/s41575-018-0026-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
392 Zarębska-michaluk D, Jaroszewicz J, Janczewska E, Berak H, Horban A, Sitko M, Garlicki A, Dobracka B, Czauż-andrzejuk A, Dybowska D, Halota W, Pawłowska M, Tudrujek-zdunek M, Tomasiewicz K, Mazur W, Deroń Z, Belica-wdowik T, Baka-ćwierz B, Buczyńska I, Simon K, Piekarska A, Białkowska-warzecha J, Lorenc B, Krygier R, Staniaszek A, Klapaczyński J, Citko J, Socha Ł, Wawrzynowicz-syczewska M, Laurans Ł, Flisiak R. Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.80761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
393 Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother 2017;18:1235-42. [PMID: 28644739 DOI: 10.1080/14656566.2017.1346609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
394 La Manna G. HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs). J Nephrol 2018;31:185-7. [PMID: 29411309 DOI: 10.1007/s40620-018-0476-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
395 Kim JR, Hwang JY, Yoon HM, Jung AY, Lee JS, Kim JS, Namgoong JM, Kim DY, Oh SH, Kim KM, Cho YA. Risk Estimation for Biliary Atresia in Patients with Neonatal Cholestasis: Development and Validation of a Risk Score. Radiology 2018;288:262-9. [PMID: 29634437 DOI: 10.1148/radiol.2018172390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
396 Ji F, Tian C, Li Z, Deng H, Nguyen MH. Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older: . European Journal of Gastroenterology & Hepatology 2017;29:977-9. [DOI: 10.1097/meg.0000000000000873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
397 Schønning K, Pedersen MS, Johansen K, Landt B, Nielsen LG, Weis N, Westh H. Analytical and clinical performance of the Hologic Aptima HCV Quant Dx Assay for the quantification of HCV RNA in plasma samples. J Virol Methods 2017;248:159-65. [PMID: 28732692 DOI: 10.1016/j.jviromet.2017.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
398 Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty 2019;8:17. [PMID: 30871599 DOI: 10.1186/s40249-019-0528-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
399 Tacke F, Mauss S. A not so easy genotype-striking regional differences in SOF/RBV treatment responses in HCV GT2. Liver Int 2017;37:1253-4. [PMID: 28710821 DOI: 10.1111/liv.13447] [Reference Citation Analysis]
400 Sharafi H, Behnava B, Azizi-Saraji A, Namvar A, Anvar A, Salimi S, Alavian SM. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virol J 2021;18:199. [PMID: 34620204 DOI: 10.1186/s12985-021-01659-0] [Reference Citation Analysis]
401 Roncero C, Ryan P, Littlewood R, Macías J, Ruiz J, Seijo P, Palma-Álvarez RF, Vega P. Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder. Hepat Med 2019;11:1-11. [PMID: 30613166 DOI: 10.2147/HMER.S187133] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
402 Craxì L. HCV Eradication: A Duty of the State, an Option for the Individual. Adv Exp Med Biol 2020;1282:85-91. [PMID: 31808124 DOI: 10.1007/5584_2019_452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
403 Suda T, Shimakami T, Shirasaki T, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Reactivation of hepatitis B virus from an isolated anti-HBc positive patient after eradication of hepatitis C virus with direct-acting antiviral agents. Journal of Hepatology 2017;67:1108-11. [DOI: 10.1016/j.jhep.2017.07.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
404 Gilleece DY, Tariq DS, Bamford DA, Bhagani DS, Byrne DL, Clarke DE, Clayden MP, Lyall DH, Metcalfe DR, Palfreeman DA, Rubinstein DL, Sonecha MS, Thorley DL, Tookey DP, Tosswill MJ, Utting MD, Welch DS, Wright MA. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Med 2019;20 Suppl 3:s2-s85. [PMID: 30869192 DOI: 10.1111/hiv.12720] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
405 Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:F1000 Faculty Rev-921. [PMID: 30002817 DOI: 10.12688/f1000research.14841.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
406 Devresse A, Delire B, Lazarus JV, Kabamba B, De Meyer M, Mourad M, Buemi A, Darius T, Cambier JF, Goffin E, Jadoul M, Kanaan N. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era. Transplant Proc 2020;52:815-22. [PMID: 32143864 DOI: 10.1016/j.transproceed.2020.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
407 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Microbes Infect 2019;21:263-70. [PMID: 31295571 DOI: 10.1016/j.micinf.2019.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
408 Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration. BMC Nurs 2019;18:23. [PMID: 31210751 DOI: 10.1186/s12912-019-0347-x] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
409 Lee YC, Hu TH, Hung CH, Lu SN, Chen CH, Wang JH. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. PLoS One 2019;14:e0214323. [PMID: 30939158 DOI: 10.1371/journal.pone.0214323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
410 Chamorro-de-Vega E, Gimenez-Manzorro A, Sanjurjo M; GRUVIC Study Group. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports. Med Clin (Barc) 2018;151:85-6. [PMID: 29295791 DOI: 10.1016/j.medcli.2017.10.041] [Reference Citation Analysis]
411 Pisaturo M, Minichini C, Starace M, Caroprese M, Macera M, Brancaccio G, De Pascalis S, Santonicola A, Galeota Lanza A, Zampino R, Cotticelli G, Sagnelli E, Gaeta GB, Coppola N. Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12. Liver Int 2019;39:844-53. [PMID: 30554459 DOI: 10.1111/liv.14025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
412 Roediger A, Wilsdon T, Haderi A, Pendleton K, Azais B. Competition between on-patent medicines in Europe. Health Policy 2019;123:652-60. [PMID: 31176459 DOI: 10.1016/j.healthpol.2019.05.009] [Reference Citation Analysis]
413 Bradshaw D, Bibby DF, Manso CF, Piorkowska R, Mohamed H, Ledesma J, Bubba L, Chan YT, Ngui SL, Carne S, Mbisa JL; STOP-HCV Consortium. Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. Clin Microbiol Infect 2021:S1198-743X(21)00373-6. [PMID: 34245902 DOI: 10.1016/j.cmi.2021.06.042] [Reference Citation Analysis]
414 Maev IV, Kuznetsova EI, Andreev DN, Dicheva DT. [Diagnostic accuracy of predictive indexes of liver fibrosis in patients with chronic hepatitis C]. Ter Arkh 2020;92:24-8. [PMID: 32598714 DOI: 10.26442/00403660.2020.02.000261] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
415 Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore) 2020;99:e21270. [PMID: 32791706 DOI: 10.1097/MD.0000000000021270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
416 Oloruntoba OO, Muir AJ. Hepatocellular Carcinoma Risk After Hepatitis C Cure. Curr Treat Options Infect Dis 2018;10:330-6. [DOI: 10.1007/s40506-017-0139-3] [Reference Citation Analysis]
417 Fabrizio C, Saracino A, Scudeller L, Milano E, Dell'Acqua R, Bruno G, Lo Caputo S, Monno L, Milella M, Angarano G. The elderly and direct antiviral agents: Constraint or challenge? Dig Liver Dis. 2017;49:1036-1042. [PMID: 28651903 DOI: 10.1016/j.dld.2017.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
418 Brouard C, Boussac-Zarebska M, Silvain C, Durand J, de Lédinghen V, Pillonel J, Delarocque-Astagneau E. Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015. BMC Infect Dis 2017;17:784. [PMID: 29262788 DOI: 10.1186/s12879-017-2889-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
419 Pisaturo M, Starace M, Minichini C, De Pascalis S, Occhiello L, Fraia AD, Messina V, Sangiovanni V, Claar E, Coppola N; CampC Network. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals. Int J Antimicrob Agents 2020;56:106067. [PMID: 32599227 DOI: 10.1016/j.ijantimicag.2020.106067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
420 Wu S, Chu C, Su C, Lin C, Lee S, Wang Y, Lee F, Huang Y, Hou M. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Journal of the Chinese Medical Association 2019;82:693-8. [DOI: 10.1097/jcma.0000000000000148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
421 Rhodes T, Lancaster K. How to think with models and targets: Hepatitis C elimination as a numbering performance. Int J Drug Policy 2021;88:102694. [PMID: 32245664 DOI: 10.1016/j.drugpo.2020.102694] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
422 Baatarkhuu O, Lee JS, Amarsanaa J, Kim DY, Ahn SH, Naranzul N, Enkhtuya D, Choijamts N, Batbayar P, Otgonbayar R, Saruul BU, Gantuul C, Gegeebadrakh B, Tuvshinbayar N, Badamsuren D, Ulzmaa G, Otgonbold J, Han KH. Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. Clin Mol Hepatol 2021;27:125-35. [PMID: 33242929 DOI: 10.3350/cmh.2020.0023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
423 Isakov V, Paduta D, Viani RM, Enejosa JV, Pasechnikov V, Znoyko O, Ogurtsov P, Bogomolov PO, Maevskaya MV, Chen X, Shulman NS. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV). Eur J Gastroenterol Hepatol 2018;30:1073-6. [PMID: 29762255 DOI: 10.1097/MEG.0000000000001166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
424 Al-Salama ZT, Deeks ED. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4. Drugs. 2017;77:911-921. [PMID: 28417245 DOI: 10.1007/s40265-017-0739-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
425 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Fajardo A, Soñora M, Cristina J, Hernández N, Moreno P. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Dis Markers 2018;2018:2514901. [PMID: 30186532 DOI: 10.1155/2018/2514901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
426 Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, Kumada H. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Adv Ther 2020;37:457-76. [PMID: 31808054 DOI: 10.1007/s12325-019-01166-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
427 Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'unto C, Francioso S, Brega A, Montalbano M, Visco-comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'offizi G, Gasbarrini A, De Santis A, Angelico M. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2018;25:1493-500. [DOI: 10.1111/jvh.12982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
428 Kalafateli M, Zisimopoulos K, Vourli G, Rigamonti C, Goulis J, Manesis E, Manolakopoulos S, Tsochatzis E, Georgiou A, Diamantopoulou G, Thomopoulos K, Gogos C, Touloumi G, Akriviadis E, Lambropoulou-Karatza C, Triantos C. Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. Dig Dis Sci 2017;62:1363-72. [PMID: 28251503 DOI: 10.1007/s10620-017-4504-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
429 Dietz J, Kalinina OV, Vermehren J, Peiffer K, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C; European HCV Resistance Study Group. Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat 2020;27:974-86. [DOI: 10.1111/jvh.13322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
430 Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66:27-36. [PMID: 28240789 DOI: 10.1002/hep.29135] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 16.8] [Reference Citation Analysis]
431 Martini S, Tandoi F, Terzi di Bergamo L, Strona S, Lavezzo B, Sacco M, Maione F, Gonella F, Strignano P, Dell Olio D, Salizzoni M, Saracco GM, Romagnoli R. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients. Liver Transpl 2017;23:915-24. [PMID: 28422425 DOI: 10.1002/lt.24772] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
432 Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. J Viral Hepat 2019;26:329-36. [PMID: 30412325 DOI: 10.1111/jvh.13037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
433 Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 2019;49:1052-9. [PMID: 30874328 DOI: 10.1111/apt.15222] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
434 Nabeel MM, Darwish RK, Alakel W, Maher R, Mostafa H, Hashem A, Elbeshlawy M, Abul-fotouh A, Shousha HI, Saeed Marie M. Changes in Serum Interferon Gamma and Interleukin-10 in Relation to Direct-Acting Antiviral Therapy of Chronic Hepatitis C Genotype 4: A Pilot Study. Journal of Clinical and Experimental Hepatology 2022;12:428-34. [DOI: 10.1016/j.jceh.2021.06.018] [Reference Citation Analysis]
435 Semenova T, Nemoz B, Thibault V, Lagathu G, Duverlie G, Brochot E, Trimoulet P, Payan C, Vallet S, Henquell C, Chevaliez S, Bouvier-Alias M, Maylin S, Roque-Afonso AM, Izquierdo L, Lunel-Fabiani F, Marcellin P, Morand P, Leroy V, Larrat S. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study. Epidemiol Infect 2019;147:e234. [PMID: 31364570 DOI: 10.1017/S0950268819001225] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
436 Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol 2018; 24(28): 3181-3191 [PMID: 30065564 DOI: 10.3748/wjg.v24.i28.3181] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
437 Cuadrado A, Llerena S, Cobo C, Pallás JR, Mateo M, Cabezas J, Fortea JI, Alvarez S, Pellón R, Crespo J, Echevarría S, Ayesa R, Setién E, Lopez-Hoyos M, Crespo-Facorro B, Agüero J, Chueca N, Garcia F, Calleja JL, Crespo J. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol 2018;113:1639-48. [PMID: 29946175 DOI: 10.1038/s41395-018-0157-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
438 Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122-1129. [PMID: 28315983 DOI: 10.1007/s00535-017-1328-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
439 Karchava M, Chkhartishvili N, Sharvadze L, Abutidze A, Dvali N, Gatserelia L, Dzigua L, Bolokadze N, Dolmazashvili E, Kotorashvili A, Imnadze P, Gamkrelidze A, Tsertsvadze T. Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program. Hepatol Res 2018;48:36-44. [PMID: 28258606 DOI: 10.1111/hepr.12890] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Rodriguez C, Soulier A, Demontant V, Poiteau L, Mercier-Darty M, Bouvier-Alias M, Pawlotsky JM, Chevaliez S. A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination. Sci Rep 2018;8:4180. [PMID: 29520035 DOI: 10.1038/s41598-018-22614-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
441 Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. Int J Drug Policy 2017;47:230-8. [PMID: 28633998 DOI: 10.1016/j.drugpo.2017.05.040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
442 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
443 Alsebaey A, Elhelbawy M, Waked I. Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease. Eur J Gastroenterol Hepatol. 2018;30:207-211. [PMID: 29240565 DOI: 10.1097/meg.0000000000001013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
444 Taneja S, Duseja A, De A, Kumar V, Ramachandran R, Sharma A, Dhiman RK, Gupta KL, Chawla Y. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. Nephrology (Carlton) 2018;23:876-82. [PMID: 28703905 DOI: 10.1111/nep.13109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
445 Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatol Int 2018;12:339-47. [PMID: 29663115 DOI: 10.1007/s12072-018-9861-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
446 Chan H, Hassali MA, Md Said R, Abu Hassan MR. Treatment Coverage and Drug Expenditure in Hepatitis C Patients From 2013 to 2019: A Journey of Improving Treatment Accessibility in Malaysia Through Government-led Initiatives. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.107372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
447 Zhang Y, Zhang Y, Liang H, Zhuo Z, Fan P, Chen Y, Zhang Z, Zhang W. Serum N-terminal DDR1: A Novel Diagnostic Marker of Liver Fibrosis Severity. J Clin Transl Hepatol 2021;9:702-10. [PMID: 34722185 DOI: 10.14218/JCTH.2021.00024] [Reference Citation Analysis]
448 El-Sheikh RM, Mansy SS, Nessim IG, Hosni HN, El Hindawi A, Hassanein MH, AbdelFattah AS. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. APMIS. 2019;127:93-105. [PMID: 30698308 DOI: 10.1111/apm.12917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
449 Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 19.4] [Reference Citation Analysis]
450 Papaluca T, O'Keefe J, Bowden S, Doyle JS, Stoove M, Hellard M, Thompson AJ. Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. J Clin Virol 2019;120:84-7. [PMID: 31606586 DOI: 10.1016/j.jcv.2019.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
451 Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018;69:18-24. [PMID: 29505844 DOI: 10.1016/j.jhep.2018.02.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 14.5] [Reference Citation Analysis]
452 Yakoot M, Abdo AM, Abdel-Rehim S, Helmy S. Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial. EBioMedicine 2017;21:182-7. [PMID: 28647541 DOI: 10.1016/j.ebiom.2017.05.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
453 Benson AA, Wolf D, Lederman N, Safadi R. Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak. Dig Liver Dis 2018;50:630-2. [PMID: 29628358 DOI: 10.1016/j.dld.2018.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
454 Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, Hardikar W, Kersey K, Massetto B, Kanwar B, Brainard DM, Shao J, Svarovskaia E, Kirby B, Arnon R, Murray KF, Schwarz KB. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102-1110. [PMID: 28543053 DOI: 10.1002/hep.29278] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 14.4] [Reference Citation Analysis]
455 Lüllau A, Petroff D, Bätz O, Kramer J, Jedrysiak K, Tenckhoff H, Berg T, Wolffram I, Wiegand J. Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. Eur J Gastroenterol Hepatol 2018;30:280-3. [PMID: 29324587 DOI: 10.1097/MEG.0000000000001052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
456 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
457 Yang M, Rao HY, Feng B, Wu E, Wei L, Lok AS. Patient Education Improves Patient Knowledge and Acceptance on Antiviral Therapy of Hepatitis C in Rural China. Chin Med J (Engl) 2017;130:2750-1. [PMID: 29133766 DOI: 10.4103/0366-6999.218023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
458 Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Ooka Y, Ogasawara S, Chiba T, Saito T, Haga Y. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. Int J Mol Sci. 2017;18. [PMID: 28441362 DOI: 10.3390/ijms18050906] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
459 Akin M, Buldukoglu OC, Adanir H, Suleymanlar I, Dincer D, Yildirim B. Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience. SAGE Open Med 2018;6:2050312118781416. [PMID: 29899985 DOI: 10.1177/2050312118781416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
460 Attia D, Deterding K, Cornberg J, Gebel MJ, Cornberg M, Manns MP, Wedemeyer H, Potthoff A. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. European Journal of Gastroenterology & Hepatology 2019;31:67-74. [DOI: 10.1097/meg.0000000000001259] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
461 Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med 2017;6:E111. [PMID: 29186062 DOI: 10.3390/jcm6120111] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
462 Pérez AB, Chueca N, García F. Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long? Germs 2017;7:40-4. [PMID: 28331841 DOI: 10.18683/germs.2017.1107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
463 Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. World J Hepatol 2018; 10(10): 639-644 [PMID: 30386457 DOI: 10.4254/wjh.v10.i10.639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
464 Warkad SD, Nimse SB, Song KS, Chantratita W, Pongthanapisith V, Nawale LU, Kim T. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018;15:107. [PMID: 29996859 DOI: 10.1186/s12985-018-1017-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
465 Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection 2018;46:607-15. [PMID: 29808463 DOI: 10.1007/s15010-018-1157-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
466 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
467 Morales MR, Sendra C, Romero-Gomez M. Hepatitis B and NAFLD: Lives Crossed. Ann Hepatol 2017;16:185-7. [PMID: 28233740 DOI: 10.5604/16652681.1231556] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
468 Bruno G, Saracino A, Milella M, Angarano G. Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2. Liver Int 2017;37:1252-3. [PMID: 28380274 DOI: 10.1111/liv.13439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
469 Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. Liver Int. 2019;39:1292-1306. [PMID: 30983083 DOI: 10.1111/liv.14119] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
470 Petta S, Rini F, Calvaruso V, Cammà C, Ciminnisi S, Di Marco V, Giannini EG, Grimaudo S, Maria Pipitone R, Craxì A. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. Liver Int 2020;40:530-8. [PMID: 31507057 DOI: 10.1111/liv.14250] [Reference Citation Analysis]
471 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
472 Lee HW, Yoo KY, Won JW, Kim HJ. Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. Gut Liver 2017;11:721-7. [PMID: 28874040 DOI: 10.5009/gnl17209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
473 Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, Verbon A, Boucher CAB, Nichols BE, van de Vijver DAMC. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One 2019;14:e0210179. [PMID: 30629662 DOI: 10.1371/journal.pone.0210179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
474 Lohmann V. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Med Microbiol Immunol 2019;208:3-24. [PMID: 30298360 DOI: 10.1007/s00430-018-0566-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
475 Purcell LN, Charles A. Liver transplantation for Hepatitis C patients in the era of direct-acting antiviral treatment: An evolving revolution - An invited commentary on "Liver transplantation for Hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study". Int J Surg 2020;76:48. [PMID: 32105892 DOI: 10.1016/j.ijsu.2020.02.022] [Reference Citation Analysis]
476 Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection 2018;46:717-20. [PMID: 29804205 DOI: 10.1007/s15010-018-1158-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
477 Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol 2018;33:2029-36. [PMID: 29864213 DOI: 10.1111/jgh.14301] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
478 Smit C, Boyd A, Rijnders BJA, van de Laar TJW, Leyten EM, Bierman WF, Brinkman K, Claassen MAA, den Hollander J, Boerekamps A, Newsum AM, Schinkel J, Prins M, Arends JE, Op de Coul ELM, van der Valk M, Reiss P;  ATHENA observational cohort. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Lancet HIV. 2021;8:e96-e105. [PMID: 33357835 DOI: 10.1016/s2352-3018(20)30301-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
479 Gallach M, Vergara M, da Costa JP, Miquel M, Casas M, Sanchez-Delgado J, Dalmau B, Rudi N, Parra I, Monllor T, Sanchez-Lloansí M, Dosal A, Valero O, Calvet X. Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS One 2018;13:e0208112. [PMID: 30566421 DOI: 10.1371/journal.pone.0208112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
480 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
481 Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and older people. World J Hepatol 2019; 11(9): 663-677 [PMID: 31598192 DOI: 10.4254/wjh.v11.i9.663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
482 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
483 Maghrabi HME, Elmowafy AY, Refaie AF, Elbasiony MA, Shiha GE, Rostaing L, Bakr MA. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. Int Urol Nephrol 2019;51:2295-304. [PMID: 31531807 DOI: 10.1007/s11255-019-02272-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
484 Tao W, Gan T, Lu J, Zhong J. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. Antiviral Res 2017;139:18-24. [PMID: 28025084 DOI: 10.1016/j.antiviral.2016.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
485 Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis 2019;21:e13047. [PMID: 30615227 DOI: 10.1111/tid.13047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
486 Gualerzi A, Bellan M, Smirne C, Tran Minh M, Rigamonti C, Burlone ME, Bonometti R, Bianco S, Re A, Favretto S, Bellomo G, Minisini R, Carnevale Schianca GP, Pirisi M. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. PLoS One 2018;13:e0209216. [PMID: 30571711 DOI: 10.1371/journal.pone.0209216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
487 Huang C, Liu L, Wang H, Fang M, Feng H, Li Y, Wang M, Tong L, Xiao X, Wang Z, Xu X, He Y, Gao C. Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study. Clin Chem Lab Med 2021;59:1087-97. [PMID: 33554541 DOI: 10.1515/cclm-2020-1588] [Reference Citation Analysis]
488 Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty MI, Ramadan M. A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure. J Hepatol 2018;68:1313-5. [PMID: 29625827 DOI: 10.1016/j.jhep.2018.03.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
489 Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Ann Hepatol 2019;18:434-8. [PMID: 31023614 DOI: 10.1016/j.aohep.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
490 Sun J, Liang X, Fan R, Hou J. Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all? Aliment Pharmacol Ther 2018;47:853-4. [PMID: 29446138 DOI: 10.1111/apt.14530] [Reference Citation Analysis]
491 Kao J, Yu M, Peng C, Heo J, Chu C, Chang T, Lee Y, Hu T, Yoon KT, Paik SW, Lim YS, Ahn SH, Isakov V, Mcphee F, Hu W, Scott Swenson E, Yin PD, Treitel M. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1: Fixed-dose DCV/ASV/BCV for HCV GT-1. Journal of Gastroenterology and Hepatology 2017;32:1998-2005. [DOI: 10.1111/jgh.13796] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
492 Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:631-43. [PMID: 28689598 DOI: 10.1016/j.cld.2017.03.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
493 Kawabe N, Hashimoto S, Yoshioka K. Editorial: comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C. Aliment Pharmacol Ther 2019;49:116-7. [PMID: 30548317 DOI: 10.1111/apt.15051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
494 Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, Rinaldi L. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379-1382. [PMID: 29228501 DOI: 10.1111/jgh.14067] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
495 Merat S; SD1000 Research Team. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clin Infect Dis 2020;70:2206-12. [PMID: 31504303 DOI: 10.1093/cid/ciz628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
496 Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69:785-792. [PMID: 30227916 DOI: 10.1016/j.jhep.2018.05.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
497 Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int 2018;38:1571-5. [PMID: 29377566 DOI: 10.1111/liv.13708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
498 Ryu H, Ahn SJ, Yoon JH, Lee JM. Inter-platform reproducibility of liver stiffness measured with two different point shear wave elastography techniques and 2-dimensional shear wave elastography using the comb-push technique. Ultrasonography 2019;38:345-54. [PMID: 31500403 DOI: 10.14366/usg.19001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
499 Bert F, Stahmeyer JT, Parpalea AL, Rossol S. Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness. Gastroenterology Res 2021;14:31-40. [PMID: 33737997 DOI: 10.14740/gr1347] [Reference Citation Analysis]
500 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018;13:e0199760. [PMID: 29953518 DOI: 10.1371/journal.pone.0199760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
501 Sulkowski MS, Feld JJ, Lawitz E, Felizarta F, Corregidor AM, Khalid O, Ghalib R, Smith WB, Van Eygen V, Luo D, Vijgen L, Gamil M, Kakuda TN, Ouwerkerk-Mahadevan S, Van Remoortere P, Beumont M. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. J Viral Hepat 2018;25:631-9. [PMID: 29274193 DOI: 10.1111/jvh.12853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
502 Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res 2017;120:97-108. [PMID: 28336373 DOI: 10.1016/j.phrs.2017.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
503 Romeo I, Marascio N, Pavia G, Talarico C, Costa G, Alcaro S, Artese A, Torti C, Liberto MC, Focà A. Structural Modeling of New Polymorphism Clusters of HCV Polymerase Isolated from Direct‐Acting Antiviral Naïve Patients: Focus on Dasabuvir and Setrobuvir Binding Affinity. ChemistrySelect 2018;3:6009-17. [DOI: 10.1002/slct.201800649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
504 Chevallier E, Büchler M, Caillard S, Bouvier N, Colosio C, Rivalan J, Sayegh J, Bertrand D, Le Meur Y, Thierry A, Garrouste C, Rerolle JP, Rostaing L, Gatault P. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience. Transplant Proc 2020;52:3179-85. [PMID: 32636068 DOI: 10.1016/j.transproceed.2020.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
505 Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018;67:514-523. [PMID: 28926120 DOI: 10.1002/hep.29541] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 20.8] [Reference Citation Analysis]
506 Brook G, Brockmeyer N, van de Laar T, Schellberg S, Winter AJ. 2017 European guideline for the screening, prevention and initial management of hepatitis B and C infections in sexual health settings. Int J STD AIDS 2018;29:949-67. [PMID: 29716442 DOI: 10.1177/0956462418767576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
507 Dhiman RK, Grover GS, Premkumar M, Taneja S, Duseja A, Rathi S, Satsangi S. Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. J Pediatr Gastroenterol Nutr 2019;68:74-80. [PMID: 30211847 DOI: 10.1097/MPG.0000000000002139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
508 Flisiak R, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Simon K, Piekarska A, Tronina O, Tuchendler E, Garlicki A. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. J Viral Hepat 2018;25:1298-305. [PMID: 29888828 DOI: 10.1111/jvh.12945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
509 Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. Gastroenterology 2018;154:976-988.e4. [PMID: 29146520 DOI: 10.1053/j.gastro.2017.11.007] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 16.6] [Reference Citation Analysis]
510 Lund Laursen T, Brøckner Siggard C, Kazankov K, Damgaard Sandahl T, Møller HJ, Ong A, Douglas MW, George J, Tarp B, Hagelskjaer Kristensen L, Lund Laursen A, Hiramatsu A, Nakahara T, Chayama K, Grønbaek H. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. Scandinavian Journal of Gastroenterology 2018;53:986-93. [DOI: 10.1080/00365521.2018.1481996] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
511 Zhang W, Liu L, Zhang M, Zhang F, Peng C, Zhang B, Chen J, Li L, He J, Xiao J, Feng Y, Wang X, Xiong A, Yang L, Zou X, Yu Y, Zhuge Y. Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome. J Clin Transl Hepatol 2021;9:345-52. [PMID: 34221920 DOI: 10.14218/JCTH.2020.00124] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
512 Perrillo RP. Hepatitis B virus reactivation during direct-acting antiviral treatment of chronic hepatitis C: A hidden danger of an otherwise major success story: Perrillo. Hepatology 2017;66:4-6. [DOI: 10.1002/hep.29185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
513 Macbeth K, Davidson K, Anderson J. Treating hepatitis C in a dedicated GP practice for homeless patients: a multidisciplinary approach. Gastrointestinal Nursing 2018;16:S29-36. [DOI: 10.12968/gasn.2018.16.sup10.s29] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
514 Doyle A, Feld JJ. Overcoming the resistance to resistance testing: Collecting the data. Liver Int 2017;37:506-8. [PMID: 28371101 DOI: 10.1111/liv.13360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
515 Auma AWN, Shive C, Damjanovska S, Kowal C, Cohen DE, Bhattacharya D, Alston-Smith B, Osborne M, Kalayjian R, Balagopal A, Sulkowski M, Wyles D, Anthony DD. T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy. Open Forum Infect Dis 2021;8:ofab079. [PMID: 33880389 DOI: 10.1093/ofid/ofab079] [Reference Citation Analysis]
516 Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. J Viral Hepat 2017;24:442-53. [DOI: 10.1111/jvh.12681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
517 Sokal EM. Direct-acting antivirals for paediatric HCV: we got there. Nat Rev Gastroenterol Hepatol 2017;14:452-3. [PMID: 28743935 DOI: 10.1038/nrgastro.2017.92] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
518 Staufer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, Dienes HP, Kivaranovic D, Schachner C, Zeitlinger M, Wulkersdorfer B, Rauch P, Prager G, Trauner M, Mikulits W. The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death Dis. 2017;8:e3135. [PMID: 29072690 DOI: 10.1038/cddis.2017.554] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
519 Fedorchenko SV, Martynovych T, Klimenko Z, Solianyk I. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors. J Med Virol 2021;93:4975-81. [PMID: 33704798 DOI: 10.1002/jmv.26935] [Reference Citation Analysis]
520 Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803-1809. [PMID: 28220512 DOI: 10.1002/hep.29130] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
521 Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infect Dis 2019;19:1019. [PMID: 31791253 DOI: 10.1186/s12879-019-4524-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
522 Theise ND, Jia J, Sun Y, Wee A, You H. Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. Mod Pathol. 2018;31:1191-1200. [PMID: 29700417 DOI: 10.1038/s41379-018-0048-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
523 Russo FP, Zanetto A, Campello E, Bulato C, Shalaby S, Spiezia L, Gavasso S, Franceschet E, Radu C, Senzolo M, Burra P, Lisman T, Simioni P. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int. 2018;38:2210-2218. [PMID: 29738632 DOI: 10.1111/liv.13873] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
524 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Lewandowski Z, Kowalik-Mikołajewska B, Marczyńska M. Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals. Minerva Pediatr (Torino) 2022;74:23-30. [PMID: 33438851 DOI: 10.23736/S2724-5276.20.05881-8] [Reference Citation Analysis]
525 Cardoso H, Silva M. Health-Related Quality of Life in Chronic Hepatitis C. GE Port J Gastroenterol 2017;24:55-7. [PMID: 28848783 DOI: 10.1159/000453319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
526 Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017;2:814-823. [PMID: 28802814 DOI: 10.1016/s2468-1253(17)30163-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
527 Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, Akahane T, Joko K, Yagisawa H, Takezawa J, Nakata R, Kusakabe A, Kojima Y, Kimura H, Tamada T, Kobashi H, Mitsuda A, Kondou M, Ogawa C, Uchida Y, Sohda T, Narita R, Izumi N. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol 2018;53:1142-50. [PMID: 29626296 DOI: 10.1007/s00535-018-1455-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
528 Puigvehí M, De Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, De la Vega J, Calleja JL, Carrión JA. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort. Liver Int 2019;39:90-7. [PMID: 30160363 DOI: 10.1111/liv.13950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
529 Masarone M, Caruso R, Aglitti A, Izzo C, De Matteis G, Attianese MR, Pagano AM, Persico M. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. Dig Liver Dis 2020;52:541-6. [PMID: 32234417 DOI: 10.1016/j.dld.2020.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
530 Hussein HA, Allam AS, Moaty ASA. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir. Curr Diabetes Rev 2020;16:165-70. [PMID: 31146663 DOI: 10.2174/1573399815666190531091128] [Reference Citation Analysis]
531 Eisenberger U, Friebus-Kardash J, Guberina H, Kribben A, Witzke O, Willuweit K, Gerken G, Herzer K. Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. Transplant Direct 2019;5:e419. [PMID: 30656217 DOI: 10.1097/TXD.0000000000000860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
532 Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48:802-809. [PMID: 29504692 DOI: 10.1111/hepr.13074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
533 Papadopoulos N, Papavdi M, Pavlidou A, Konstantinou D, Kranidioti H, Kontos G, Koskinas J, Papatheodoridis GV, Manolakopoulos S, Deutsch M. Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues. Ann Gastroenterol 2018;31:365-70. [PMID: 29720863 DOI: 10.20524/aog.2018.0255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
534 Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. Journal of Hepatology 2019;70:874-84. [DOI: 10.1016/j.jhep.2019.01.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
535 Wang L, Chen W, Xi W, Feng J, Dang P, Ma Y, Yu Y. Utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections. J Med Virol 2017;89:1235-40. [PMID: 27958657 DOI: 10.1002/jmv.24754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
536 Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, Shalimar. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography. J Clin Exp Hepatol 2019;9:207-14. [PMID: 31024203 DOI: 10.1016/j.jceh.2018.06.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
537 Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, Manzano ML, Lorente S, Testillano M, Xiol X. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol. 2017;67:1168-1176. [PMID: 28842296 DOI: 10.1016/j.jhep.2017.08.008] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 14.0] [Reference Citation Analysis]
538 Wong YJ, Chew SY, Hsiang JC, Thurairajah PH, Kumar R, Teo EK, Gokhale RS, Noor IBM, Tan J. VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature. Clin Mol Hepatol 2019;25:218-22. [PMID: 30184617 DOI: 10.3350/cmh.2018.0017] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
539 Mancuso ME, Linari S, Santagostino E, Bartolozzi D, D'Ambrosio R, Borghi M, Lampertico P, Peyvandi F, Castaman G, Aghemo A. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. Liver Int 2020;40:1062-8. [PMID: 31876354 DOI: 10.1111/liv.14337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
540 Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang H, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su F, Wan S, Zeng Z, Chen H, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. The Lancet Gastroenterology & Hepatology 2017;2:805-13. [DOI: 10.1016/s2468-1253(17)30159-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
541 Li Y, Li L, Liu J, Zhang DW, Zhao F, Wang L, Mahemure A, Xie R, Lei S, Cai W, Wang X, Shu Z, Chen X, Wang H, Wang FS. Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China. Hepatol Int 2018;12:465-73. [PMID: 30203381 DOI: 10.1007/s12072-018-9891-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
542 Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H, D'Alteroche L, Leroy V, Bourliere M, Hubert-Fouchard I, Guyader D, Rosa I, Nguyen-Khac E, Fedchuk L, Akremi R, Bennai Y, Filipovics A, Zhao Y, Bronowicki JP. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int 2017;37:1314-24. [PMID: 28177199 DOI: 10.1111/liv.13383] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
543 Bwa AH, Nangia G, Win STS, Maung ST, Han KAW, Htar SS, Wine LY, Ko WW, Oo MP, Hlaing NKT, Palecki J, Loza BL, Win KM, Reddy R. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience. J Clin Exp Hepatol 2019;9:283-93. [PMID: 31360020 DOI: 10.1016/j.jceh.2018.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
544 Mazouz S, Boisvert M, Shoukry NH, Lamarre D. Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. CanLivJ 2018;1:78-105. [DOI: 10.3138/canlivj.1.2.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
545 Pariente A, Arpurt JP, Remy AJ, Rosa-Hezode I, Causse X, Heluwaert F, Macaigne G, Henrion J, Renou C, Schnee M, Salloum H, Hommel S, Pilette C, Arotcarena R, Barjonet G, Lison H, Bourhis F, Jouannaud V, Pauwels A, Le-Bricquir Y, Geagea E, Condat B, Ripault MP, Zanditenas D, de Montigny-Lenhardt S, Labadie H, Tissot B, Maringe E, Cadranel JF, Hagege H, Lesgourgues B; Association Nationale des Gastroenterologues des Hopitaux (ANGH). Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals. Ann Hepatol 2019;18:193-202. [PMID: 31113590 DOI: 10.5604/01.3001.0012.7912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
546 Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
547 Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG. Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol 2018;11:519-24. [PMID: 29498556 DOI: 10.1080/17512433.2018.1447923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
548 Pineda JA, Rivero-Juárez A, de Los Santos I, Collado A, Merino D, Morano-Amado LE, Ríos MJ, Pérez-Pérez M, Téllez F, Palacios R, Pérez AB, Mancebo M, Rivero A, Macías J. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice. HIV Clin Trials 2018;19:23-30. [PMID: 29447085 DOI: 10.1080/15284336.2018.1436637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
549 Skladany L, Janceková D, Svac J. Hepatitis C virus antibodies in outpatients with chronic kidney disease. Clin Exp Hepatol 2018;4:267-70. [PMID: 30603675 DOI: 10.5114/ceh.2018.80129] [Reference Citation Analysis]
550 Yoon CH, Jin YJ, Lee JW. Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area. Eur J Gastroenterol Hepatol 2018;30:1090-6. [PMID: 29847489 DOI: 10.1097/MEG.0000000000001174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
551 Tao YC, Deng R, Wang ML, Lv DD, Yuan M, Wang YH, Chen EQ, Tang H. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. Virol J 2018;15:150. [PMID: 30285800 DOI: 10.1186/s12985-018-1066-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
552 Salmon D, Mondelli MU, Maticic M, Arends JE; The ESCMID Study Group for Viral Hepatitis. The benefits of hepatitis C virus cure: Every rose has thorns. J Viral Hepat 2018;25:320-8. [DOI: 10.1111/jvh.12823] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
553 Barone M, Iannone A, Shahini E, Ippolito AM, Brancaccio G, Morisco F, Milella M, Messina V, Smedile A, Conti F, Gatti P, Santantonio T, Tundo P, Lauletta G, Napoli N, Masetti C, Termite AP, Francavilla R, Di Leo A, Pesce F, Andriulli A. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study. J Viral Hepat 2018;25:56-62. [PMID: 28787102 DOI: 10.1111/jvh.12765] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
554 Papanikolaou IS, Papadimitropoulos V. Editorial: are the "miraculous" direct-acting antiviral (DAA) regimens really safe? Aliment Pharmacol Ther 2018;47:1318-9. [PMID: 29644736 DOI: 10.1111/apt.14580] [Reference Citation Analysis]
555 Merli M, Defrancesco I, Visco C, Besson C, Di Rocco A, Arcari A, Sica A, Cencini E, Tisi MC, Frigeni M, Grossi P, Bianchi B, Mora B, Bertù L, Bruno R, Passamonti F, Arcaini L. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leuk Lymphoma 2020;61:2122-8. [PMID: 32343165 DOI: 10.1080/10428194.2020.1755859] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
556 Crowley D, Murtagh R, Cullen W, Lambert JS, McHugh T, Van Hout MC. Hepatitis C virus infection in Irish drug users and prisoners - a scoping review. BMC Infect Dis 2019;19:702. [PMID: 31395032 DOI: 10.1186/s12879-019-4218-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
557 Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty M, Ramadan M. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients. Dig Dis Sci 2018;63:1341-7. [PMID: 29546644 DOI: 10.1007/s10620-018-5005-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
558 Liu X, Meng J, Xu H, Niu J. Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e15414. [PMID: 31027143 DOI: 10.1097/MD.0000000000015414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
559 Sanai FM, Altraif IH, Alswat K, AlZanbagi A, Babatin MA, AlMousa A, Almutairi NH, Aljawad MS, Alghamdi AS, Aljumah AA, Alalwan AM, Al-Hamoudi WK, Assiri AM, Dahlan Y, Alsahafi A, Alothmani HS, AlSaleemi MS, Mousa WA, Albenmousa A, Awny A, Albiladi H, Abdo AA, AlGhamdi H. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. J Infect 2018;76:536-42. [PMID: 29742470 DOI: 10.1016/j.jinf.2018.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
560 Caviglia GP, Troshina G, Santaniello U, Rosati G, Bombaci F, Birolo G, Nicolosi A, Saracco GM, Ciancio A. Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers 2022;14:828. [DOI: 10.3390/cancers14030828] [Reference Citation Analysis]
561 Berenguer J, Calleja JL, Montes ML, Gil Á, Moreno A, Bañares R, Aldámiz-Echevarría T, Albillos A, Téllez MJ, Olveira A, Domínguez L, Fernández I, García-Samaniego J, Polo BA, Álvarez B, Ryan P, Barrio J, Devesa MJ, Benítez L, Santos I, Buey LG, Sanz J, Poves E, Losa JE, Fernández-Rodríguez C, Jarrín I, Calvo MJ, González-García J. HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. Open Forum Infect Dis 2019;6:ofz214. [PMID: 31139679 DOI: 10.1093/ofid/ofz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
562 Yu ML, Chen YL, Huang CF, Lin KH, Yeh ML, Huang CI, Hsieh MH, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. J Formos Med Assoc 2018;117:518-26. [PMID: 28662883 DOI: 10.1016/j.jfma.2017.06.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
563 Perazzo H, Luz PM. Liver disease and healthy life-expectancy with HIV. Lancet HIV 2017;4:e236-7. [PMID: 28262573 DOI: 10.1016/S2352-3018(17)30030-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
564 Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. Antimicrob Agents Chemother 2017;61:e00037-17. [PMID: 28348150 DOI: 10.1128/AAC.00037-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
565 Rust C, Gerbes A. [How to deal with increased liver markers]. MMW Fortschr Med 2017;159:68-70. [PMID: 29124577 DOI: 10.1007/s15006-017-0283-1] [Reference Citation Analysis]
566 张莹, 颜学兵. 后DAA时代抗HCV治疗的现状及存在问题. 世界华人消化杂志 2017; 25(13): 1135-1142 [DOI: 10.11569/wcjd.v25.i13.1135] [Reference Citation Analysis]
567 Rungta S, Kumari S, Verma K, Akhtar G, Deep A Sr, Swaroop S. A Comparative Analysis of the APRI, FIB4, and FibroScan Score in Evaluating the Severity of Chronic Liver Disease in Chronic Hepatitis B Patients in India. Cureus 2021;13:e19342. [PMID: 34909303 DOI: 10.7759/cureus.19342] [Reference Citation Analysis]
568 Mohr R, Boesecke C, Dold L, Schierwagen R, Schwarze-Zander C, Wasmuth JC, Weisensee I, Rockstroh JK, Trebicka J. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. Medicine (Baltimore) 2018;97:e0462. [PMID: 29702998 DOI: 10.1097/MD.0000000000010462] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
569 Hassany M, Gamal A, Zaki N, Eysa B. Assessment of the Relation Between SNP in MxA Gene and the Responsiveness of Egyptian HCV Genotype 4 Patients to Pegylated Interferon and Ribavirin Treatment. Gastroenterology Res 2017;10:100-5. [PMID: 28496530 DOI: 10.14740/gr810w] [Reference Citation Analysis]
570 Fabrizi F, Donato FM, Messa P. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis. Int J Artif Organs 2017;40:531-41. [PMID: 28708211 DOI: 10.5301/ijao.5000613] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
571 Jacobson IM, Lawitz E, Kwo PY, Hézode C, Peng CY, Howe AYM, Hwang P, Wahl J, Robertson M, Barr E, Haber BA. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology 2017;152:1372-1382.e2. [PMID: 28193518 DOI: 10.1053/j.gastro.2017.01.050] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
572 Macías J, Morano LE, Téllez F, Granados R, Rivero-Juárez A, Palacios R, Ríos M, Merino D, Pérez-Pérez M, Collado A, Figueruela B, Morano A, Freyre-Carrillo C, Martín JM, Rivero A, García F, Pineda JA; HEPAVIR group from the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) and the GEHEP group from the Sociedad Española de Enfermedades Infecciosas y Microbiología (SEIMC). Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J Hepatol 2019;71:45-51. [PMID: 30853642 DOI: 10.1016/j.jhep.2019.02.018] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
573 McClure MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, Vijgen L, Astruc B, Patat A, Westland C, Chanda S, Zhang Q, Kakuda TN, Vuong J, Khorlin N, Beigelman L, Blatt LM, Fry J. Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. PLoS One 2018;13:e0204974. [PMID: 30325939 DOI: 10.1371/journal.pone.0204974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
574 Hézode C. Treatment of hepatitis C: Results in real life. Liver Int 2018;38 Suppl 1:21-7. [PMID: 29427481 DOI: 10.1111/liv.13638] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
575 Kakuda TN, McClure MW, Westland C, Vuong J, Homery MC, Poizat G, Viguerie L, Denot C, Patat A, Zhang Q, Hui J, Apelian D, Smith DB, Chanda SM, Fry J. Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. Pharmacol Res Perspect 2018;6:e00395. [PMID: 29736243 DOI: 10.1002/prp2.395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
576 Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. J Viral Hepat 2019;26:55-64. [PMID: 30265418 DOI: 10.1111/jvh.13008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
577 Occhipinti V, Farina L, Viganò M, Capecchi M, Labanca S, Fanetti I, Corradini P, Rumi M. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. Dig Liver Dis 2019;51:719-23. [PMID: 30502232 DOI: 10.1016/j.dld.2018.10.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
578 Preda CM, Popescu CP, Baicus C, Constantinescu I, Oproiu A, Voiosu T, Diculescu M, Negreanu L, Gheorghe L, Sporea I, Trifan A, Ceausu E, Proca D, Manuc M. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin. J Viral Hepat 2018;25:834-41. [PMID: 29397016 DOI: 10.1111/jvh.12872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
579 Miotto N, Mendes LC, Zanaga LP, Goncales ESL, Lazarini MSK, Pedro MN, Gonçales FL Jr, Stucchi RSB, Vigani AG. Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort. Eur J Gastroenterol Hepatol 2017;29:1149-54. [PMID: 28800033 DOI: 10.1097/MEG.0000000000000944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
580 Ghoneem E, Saleh A, El-etreby SA, Mortada MI, Ghannam MA, El-ashwah S, Eisa N. Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00124-5] [Reference Citation Analysis]
581 Renzulli M, Buonfiglioli F, Conti F, Brocchi S, Serio I, Foschi FG, Caraceni P, Mazzella G, Verucchi G, Golfieri R, Andreone P, Brillanti S. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol 2018;28:506-13. [DOI: 10.1007/s00330-017-5033-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
582 Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Aliment Pharmacol Ther 2018;48:1290-300. [PMID: 30362139 DOI: 10.1111/apt.15011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
583 Wyles D, Wedemeyer H, Ben-ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang H, Butterton J, Robertson M, Wahl J, Barr E, Joeng H, Martin E, Serfaty L; for the C-CREST Part C and C-SURGE Investigators. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure: Wyles et al. Hepatology 2017;66:1794-804. [DOI: 10.1002/hep.29358] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
584 Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation 2017;101:S1-S109. [PMID: 28742762 DOI: 10.1097/TP.0000000000001769] [Cited by in Crossref: 72] [Cited by in F6Publishing: 79] [Article Influence: 14.4] [Reference Citation Analysis]
585 Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol 2018;24:1-9. [PMID: 29249129 DOI: 10.3350/cmh.2017.0112] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 15.8] [Reference Citation Analysis]
586 Schotten C, Ostertag B, Sowa JP, Manka P, Bechmann LP, Hilgard G, Marquardt C, Wichert M, Toyoda H, Lange CM, Canbay A, Johnson P, Wedemeyer H, Best J. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients. Pharmaceuticals (Basel) 2021;14:735. [PMID: 34451832 DOI: 10.3390/ph14080735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
587 Abd Alla MDA, Elibiary SA, Elshaboury RH, Wu GY, Dawood RM, El Awady MK. HCV Therapy Follow-up Fractionation (CTF2) by Intra-PBMC Nested RNA PCR Recognizes Early Virologic Response and Relapse. J Clin Transl Hepatol 2018;6:147-54. [PMID: 29951359 DOI: 10.14218/JCTH.2017.00077] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
588 Hupa KL, Deterding K, Port K, Kimmann M, Manns MP, Wedemeyer H, Cornberg M. Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C? J Hepatol 2018;68:851-3. [PMID: 29175536 DOI: 10.1016/j.jhep.2017.10.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
589 Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment Pharmacol Ther 2017;46:432-9. [PMID: 28627791 DOI: 10.1111/apt.14177] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
590 Perales C, Chen Q, Soria ME, Gregori J, Garcia-Cehic D, Nieto-Aponte L, Castells L, Imaz A, Llorens-Revull M, Domingo E, Buti M, Esteban JI, Rodriguez-Frias F, Quer J. Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant. Infect Drug Resist 2018;11:2207-10. [PMID: 30519058 DOI: 10.2147/IDR.S172226] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
591 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20:436-446. [PMID: 31019253 DOI: 10.1038/s41435-019-0066-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
592 Carrai P, Morelli C, Cordone G, Romano A, Tamé M, Lionetti R, Pietrosi G, Lenci I, Piai G, Russo FP, Coppola C, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Martini S, Toniutto P; ITACOPS study group. The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transpl Int 2017;30:1253-65. [PMID: 28799277 DOI: 10.1111/tri.13018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
593 Zanone MM, Marinucci C, Ciancio A, Cocito D, Zardo F, Spagone E, Ferrero B, Cerruti C, Charrier L, Cavallo F, Saracco GM, Porta M. Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study. Liver Int 2021. [PMID: 34219359 DOI: 10.1111/liv.15002] [Reference Citation Analysis]
594 Vitrone M, Andini R, Mattucci I, Maiello C, Atripaldi L, Durante-Mangoni E, Zampino R. Direct antiviral treatment of chronic hepatitis C in heart transplant recipients. Transpl Infect Dis 2018;20. [PMID: 29139181 DOI: 10.1111/tid.12813] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
595 Soeiro CASP, Gonçalves CAM, Marques MSC, Méndez MJV, Tavares APRA, Horta AMLMFCA, Sarmento-Castro RMDR. Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study. BMC Infect Dis 2018;18:364. [PMID: 30075765 DOI: 10.1186/s12879-018-3278-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
596 Morillas RM, Masnou H, Ardévol M, López D. Role of ribavirin in interferon-free therapy for the treatment of hepatitisC virus. Gastroenterol Hepatol 2017;40:699-708. [PMID: 28823382 DOI: 10.1016/j.gastrohep.2017.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
597 Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. BMC Infect Dis 2017;17:361. [PMID: 28535787 DOI: 10.1186/s12879-017-2462-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
598 Trifan A, Stratina E, Rotaru A, Stafie R, Zenovia S, Nastasa R, Huiban L, Sfarti C, Cojocariu C, Cuciureanu T, Muzica C, Chiriac S, Girleanu I, Singeap A, Stanciu C. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response. Diagnostics 2022;12:702. [DOI: 10.3390/diagnostics12030702] [Reference Citation Analysis]
599 Perazzo H, Jorge MJ, Silva JC, Avellar AM, Silva PS, Romero C, Veloso VG, Mujica-Mota R, Anderson R, Hyde C, Castro R. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC Gastroenterol 2017;17:119. [PMID: 29169329 DOI: 10.1186/s12876-017-0676-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
600 Rezaee-Zavareh MS, Alavian SM. Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation. Aliment Pharmacol Ther 2017;46:76. [PMID: 28589589 DOI: 10.1111/apt.14083] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
601 Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A, Klein MB; Canadian Co-Infection Cohort Study. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. Int J Drug Policy 2019;65:41-9. [PMID: 30594080 DOI: 10.1016/j.drugpo.2018.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
602 Bourlière M, Pietri O. Hepatitis C virus therapy: No one will be left behind. Int J Antimicrob Agents 2019;53:755-60. [PMID: 30605721 DOI: 10.1016/j.ijantimicag.2018.12.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
603 Llerena S, Cabezas J, Cuadrado A, Manuel Olmos J, González M, García F, Cobo C, Crespo J. Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. Ann Hepatol 2019;18:236-9. [PMID: 31113598 DOI: 10.5604/01.3001.0012.7931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
604 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. PLoS One 2018;13:e0198642. [PMID: 29856885 DOI: 10.1371/journal.pone.0198642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
605 Yakoot M, El-Shabrawi MH, AbdElgawad MM, Mahfouz AA, Helmy S, Abdo AM, El-Khayat HR. Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2018;67:86-89. [PMID: 29570560 DOI: 10.1097/mpg.0000000000001968] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 8.7] [Reference Citation Analysis]
606 Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol 2020; 26(2): 109-133 [PMID: 31969775 DOI: 10.3748/wjg.v26.i2.109] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
607 Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. J Viral Hepat 2018;25:680-98. [PMID: 29345844 DOI: 10.1111/jvh.12866] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
608 Rendina M, Castellaneta NM, Losurdo G, Castellaneta A, Cazzolla A, Chialà C, D'Errico F, Di Leo A. Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept. Ther Adv Chronic Dis 2018;9:121-3. [PMID: 29854373 DOI: 10.1177/2040622318755651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
609 Zacharakis G, Alzahrani J. Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.12531] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
610 Elsharkawy A, Alem SA, Fouad R, El Raziky M, El Akel W, Abdo M, Tantawi O, AbdAllah M, Bourliere M, Esmat G. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol 2017;32:1624-30. [PMID: 28177543 DOI: 10.1111/jgh.13758] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
611 Andre-Garnier E, Besse B, Rodallec A, Ribeyrol O, Ferre V, Luco C, Le Guen L, Bourgeois N, Gournay J, Billaud E, Raffi F, Coste-Burel M, Imbert-Marcille BM. An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. PLoS One 2017;12:e0179562. [PMID: 28727784 DOI: 10.1371/journal.pone.0179562] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
612 Soriano V, Benítez-Gutiérrez L, Arias A, Carrasco I, Barreiro P, Peña JM, de Mendoza C. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol 2017;13:1015-22. [PMID: 28753040 DOI: 10.1080/17425255.2017.1359254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
613 Hansen JF, Hallager S, Øvrehus A, Weis N, Brehm Christensen P, Pedersen C. Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors. Open Forum Infect Dis 2018;5:ofx257. [PMID: 29367939 DOI: 10.1093/ofid/ofx257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
614 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 29.8] [Reference Citation Analysis]
615 Lauletta G, Russi S, Pavone F, Vacca A, Dammacco F. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther 2017;19:74. [PMID: 28388935 DOI: 10.1186/s13075-017-1280-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
616 Cornberg M, Petersen J, Schober A, Mauss S, Böker KHW, Link R, Günther R, Serfert Y, Pfeiffer-vornkahl H, Manns MP, Sarrazin C, Hüppe D, Berg T, Niederau C. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017;45:688-700. [DOI: 10.1111/apt.13925] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
617 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
618 Calvaruso V, Bronte F, Ferraro D, Reina G, Conte E, Rini F, Magro B, Petta S, Di Marco V, Craxì A. Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study). Liver Int 2019;39:2240-3. [PMID: 31502755 DOI: 10.1111/liv.14242] [Reference Citation Analysis]
619 Ahmed R, Kareem R, Venkatesan N, Botleroo RA, Ogeyingbo OD, Bhandari R, Gyawali M, Elshaikh AO. Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection. Cureus 2021;13:e17237. [PMID: 34540464 DOI: 10.7759/cureus.17237] [Reference Citation Analysis]
620 Duffy D, Mottez E, Ainsworth S, Buivan TP, Baudin A, Vray M, Reed B, Fontanet A, Rohel A, Petrov-Sanchez V, Abel L, Theodorou I, Miele G, Pol S, Albert ML. An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms. PLoS One 2017;12:e0183084. [PMID: 28877177 DOI: 10.1371/journal.pone.0183084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
621 Elhelbawy M, Abdel-Razek W, Alsebaey A, Hashim M, Elshenawy H, Waked I. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. Eur J Gastroenterol Hepatol 2019;31:16-23. [PMID: 30024489 DOI: 10.1097/MEG.0000000000001215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
622 Tran TH, Nguyen BT, Nguyen TA, Pham TTP, Nguyen TTT, Mai HTB, Pham HB, Nguyen TM, Phan HTT, Do NT, Ait-Ahmed M, Taieb F, Madec Y. Dried blood spots perform well to identify patients with active HCV infection in Vietnam. J Viral Hepat 2020;27:514-9. [PMID: 31981287 DOI: 10.1111/jvh.13263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
623 Bonacci M, Lens S, Mariño Z, Londoño M, Rodriguez-tajes S, Sánchez-tapias JM, Ramos-casals M, Hernández-rodríguez J, Forns X. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology 2018;155:311-315.e6. [DOI: 10.1053/j.gastro.2018.04.024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
624 Al-Khabori M, Daar S, Al-Busafi SA, Al-Dhuhli H, Alumairi AA, Hassan M, Al-Rahbi S, Al-Ajmi U. Noninvasive assessment and risk factors of liver fibrosis in patients with thalassemia major using shear wave elastography. Hematology. 2019;24:183-188. [PMID: 30453843 DOI: 10.1080/10245332.2018.1540518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
625 Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis 2018;5:ofy001. [PMID: 29450210 DOI: 10.1093/ofid/ofy001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
626 Mohamed H, Ghany WAE, Yehia R, Fouad M. Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure. Clin Exp Hepatol 2022;8:36-41. [PMID: 35415259 DOI: 10.5114/ceh.2022.114246] [Reference Citation Analysis]
627 Lim TS, Ahn SH. Use of sofosbuvir in chronic kidney disease: Is it necessary? Clin Mol Hepatol 2017;23:308-10. [PMID: 28948751 DOI: 10.3350/cmh.2017.0109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
628 Wu SH, Loong CC, Chu CJ, Su CW, Lin CC, Hsia CY, Liu C, Lee SD, Wang YJ, Lee FY, Linb NC, Chen CY, Huang YH, Hou MC. Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation. J Chin Med Assoc 2020;83:18-24. [PMID: 31714442 DOI: 10.1097/JCMA.0000000000000222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
629 Caroleo B, Colangelo L, Perticone M, De Sarro G, Gallelli L. Efficacy and Safety of Elbasvir-Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real-Life Clinical Practice. J Clin Pharmacol 2018;58:1248-53. [PMID: 29746724 DOI: 10.1002/jcph.1135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
630 Passerini M, Schiavini M, Magni CF, Landonio S, Niero F, Passerini S, Croci AL, Bolis M, Scalzi V, Gubertini G, Ricci ED, Galli M, Rizzardini G. Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience. Eur J Gastroenterol Hepatol 2018;30:1208-15. [PMID: 30138160 DOI: 10.1097/MEG.0000000000001239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
631 Singer JB, Thomson EC, Hughes J, Aranday-Cortes E, McLauchlan J, da Silva Filipe A, Tong L, Manso CF, Gifford RJ, Robertson DL, Barnes E, Ansari MA, Mbisa JL, Bibby DF, Bradshaw D, Smith D. Interpreting Viral Deep Sequencing Data with GLUE. Viruses 2019;11:E323. [PMID: 30987147 DOI: 10.3390/v11040323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
632 Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. Eur J Gastroenterol Hepatol 2018;30:291-5. [PMID: 29120906 DOI: 10.1097/MEG.0000000000001027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
633 Salomone F, Petta S, Micek A, Pipitone RM, Distefano A, Castruccio Castracani C, Rini F, Di Rosa M, Gardi C, Calvaruso V, Di Marco V, Li Volti G, Grimaudo S, Craxì A. Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. Liver Int 2020;40:2820-7. [PMID: 32666695 DOI: 10.1111/liv.14608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
634 Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration. Health Justice 2018;6:23. [PMID: 30569249 DOI: 10.1186/s40352-018-0081-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
635 Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2017;11:559-67. [PMID: 28317409 DOI: 10.1080/17474124.2017.1309284] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
636 Pessoa MG, Ramalho-Madruga JV, Alves K, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Correa MC, Ferraz ML, Ferreira PRA, Álvares-da-Silva MR, Coelho HS, Affonso-de-Araújo ES, Furtado J, Parana R, Silva G, Lari SA, Liu L, Tripathi R, Pilot-Matias T, Cohen DE, Shulman NS, Martinelli A. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. Ann Hepatol 2018;17:959-68. [PMID: 30600291 DOI: 10.5604/01.3001.0012.7196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
637 Kwon JH, Yoo SH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee SW, Lee HL, Han NI, Kim SH, Song MJ, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. J Med Virol 2019;91:1104-11. [PMID: 30695109 DOI: 10.1002/jmv.25412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
638 Heo YA, Deeks ED. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. Drugs 2018;78:577-87. [PMID: 29546556 DOI: 10.1007/s40265-018-0895-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
639 Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D, Rosenberg WM, Foster GR, Irving WL; HCV Research UK. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Aliment Pharmacol Ther 2019;50:204-14. [PMID: 31149748 DOI: 10.1111/apt.15296] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
640 Cheng PN, Chiu YC, Chien SC, Chiu HC. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. J Formos Med Assoc 2019;118:907-13. [PMID: 30316677 DOI: 10.1016/j.jfma.2018.09.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
641 Mücke MM, Mücke VT, Lange CM, Zeuzem S. Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment. Liver Int 2017;37 Suppl 1:19-25. [PMID: 28052635 DOI: 10.1111/liv.13279] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
642 Boleto G, Saadoun D, Cacoub P. Strategies to prevent persistent or relapsed mixed cryoglobulinemia. Expert Opinion on Orphan Drugs 2020;8:137-43. [DOI: 10.1080/21678707.2020.1767586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
643 Osawa M, Ueno T, Shiozaki T, Li H, Garimella T. Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects. J Clin Pharmacol 2019;59:557-65. [PMID: 30566237 DOI: 10.1002/jcph.1347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
644 Li Cavoli G, Carollo C, Oliva B, Amato A, Turdo RA, Azzolina V, Mongiovì R, Caputo F. The efficacy of antiviral therapy after renal transplant in a HCV-positive recipient from a HCV-positive donor. Nefrologia (Engl Ed) 2019;39:313-4. [PMID: 30808521 DOI: 10.1016/j.nefro.2018.11.006] [Reference Citation Analysis]
645 Scott JA, Chew KW. Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis 2017;4:18-36. [PMID: 28357062 DOI: 10.1177/2049936116681279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
646 Wu J, Zhou Y, Fu X, Deng M, Zheng Y, Tian G, Li Y, Wang C, Ding C, Ruan B, Yang S, Li L. The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study. Hepatology. 2019;69:1442-1452. [PMID: 30561833 DOI: 10.1002/hep.30476] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
647 Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21 Suppl 2:e25054. [PMID: 29633564 DOI: 10.1002/jia2.25054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
648 Hussein MH, Peedikayil MC, Zamir ZA, Alfadda A. Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents. Ann Thorac Med 2018;13:117-21. [PMID: 29675064 DOI: 10.4103/atm.ATM_194_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
649 Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67:411-431. [PMID: 28683174 DOI: 10.3322/caac.21403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
650 Ramzy I, Fouad R, Salama R, Abdellatif Z, Elsharkawy A, Zayed N, Elsharkawy M, El Akel W, Bakheet N. Evaluation of red cell distribution width to platelet ratio as a novel non-invasive index for predicting hepatic fibrosis in patients with chronic hepatitis C. Arab J Gastroenterol 2021;22:6-11. [PMID: 33664008 DOI: 10.1016/j.ajg.2020.12.003] [Reference Citation Analysis]
651 Mücke MM, Backus LI, Mücke VT, Coppola N, Preda CM, Yeh M, Tang LSY, Belperio PS, Wilson EM, Yu M, Zeuzem S, Herrmann E, Vermehren J. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2018;3:172-80. [DOI: 10.1016/s2468-1253(18)30002-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 30] [Article Influence: 20.3] [Reference Citation Analysis]
652 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
653 Khaliq S, Raza SM. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina (Kaunas) 2018;54:E80. [PMID: 30400604 DOI: 10.3390/medicina54050080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
654 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
655 Bandera A, Lorenzini P, Taramasso L, Cozzi-Lepri A, Lapadula G, Mussini C, Saracino A, Ceccherini-Silberstein F, Puoti M, Quiros-Roldan E, Montagnani F, Antinori A, d'Arminio Monforte A, Gori A; Icona Foundation Cohort. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort. J Viral Hepat 2021;28:779-86. [PMID: 33600068 DOI: 10.1111/jvh.13488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
656 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
657 Komolmit P, Kimtrakool S, Suksawatamnuay S, Thanapirom K, Chattrasophon K, Thaimai P, Chirathaworn C, Poovorawan Y. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A randomized, double-blind, placebo-controlled study. Sci Rep 2017;7:8905. [PMID: 28827788 DOI: 10.1038/s41598-017-09512-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
658 Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Hepatol Int 2018;12:348-55. [PMID: 29754329 DOI: 10.1007/s12072-018-9868-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
659 Shahini E, Iannone A, Romagno D, Armandi A, Carparelli S, Principi M, Viggiani MT, Ierardi E, Di Leo A, Barone M. Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48:1138-1145. [PMID: 30375693 DOI: 10.1111/apt.14999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
660 Walker A, Filke S, Lübke N, Obermeier M, Kaiser R, Häussinger D, Timm J, Bock HH. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure. Virol J 2017;14:106. [PMID: 28595606 DOI: 10.1186/s12985-017-0779-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
661 Malin JJ, Boesecke C, Schwarze-Zander C, Wasmuth JC, Schlabe S, Trebicka J, Spengler U, Llibre JM, Jou T, Vasylyev M, Clotet B, Rockstroh JK. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection. HIV Med 2019;20:230-6. [PMID: 30687989 DOI: 10.1111/hiv.12705] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
662 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
663 Yusrina F, Chua CW, Lee CK, Chiu L, Png TS, Khoo MJ, Yan G, Lee GH, Yan B, Lee HK. Comparison of cobas HCV GT against Versant HCV Genotype 2.0 (LiPA) with confirmation by Sanger sequencing. J Virol Methods 2018;255:8-13. [PMID: 29428399 DOI: 10.1016/j.jviromet.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
664 Stournaras E, Neokosmidis G, Stogiannou D, Protopapas A, Tziomalos K. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol 2018;30:1277-82. [PMID: 30179906 DOI: 10.1097/MEG.0000000000001254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1]